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ABSTRACT 
Cell-free protein synthesis (CFPS) is a versatile tool for protein research and 
biomanufacturing. This work goes into great detail explaining the history and 
biochemical utility of supplements used in various energy mixes. The biological role of 
each component is discussed in a way that is easily understood by newcomers to the field. 
This work also takes a unit operations approach to simplifying extract preparation, as 
well as a novel method for DNA amplification. E. coli cell growth was optimized using a 
face centered cubic designed experiment that provided an IPTG induction time of 201 
min and a harvest time of 255 min. These times correspond to 1 L of growth culture in a 
2.5 L shake flask. Experiments were then conducted to determine the optimal number 
passes through a French press homogenizer (1) as well as the best time and temperature 
combination for lyophilization (4 hr and 15 Celsius). The resulting extract was more 
effective than that of commercial kits. This can be used in conjunction with a novel DNA 
amplification method that modifies a minimal linear template for use in rolling circle 
amplification. This minimalist template showed identical expression levels to traditional 
plasmid-based expression using sfGFP. This template was used to successfully express 
multiple proteins from various classes: sfGFP, mVenus, mCherry, four previously 
uncharacterized GFP variants, chloramphenicol acetyl transferase, a chitinase catalytic 
domain, subtilisin, an anti-GFP nanobody, BP100, and CA(1-7)M(2-9). Future directions 
for the use of CFPS in developing fusion proteins and nanobodies for therapeutics will 
also be discussed.  
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CHAPTER 1.    INTRODUCTION 
 There are 4 types of organic macromolecules present in all known forms of life: 
nucleic acids (DNA and RNA), proteins, carbohydrates, and lipids. Each macromolecule 
plays an important role in living systems, but this thesis focuses on the production of proteins 
in vitro. Proteins are an extremely interesting class of compounds because of the many roles 
they fulfill in nature including structural, catalytic, signaling, and capturing. Recently the 
Nobel Prize in chemistry was awarded to scientists and engineers who use directed evolution 
to produce desired capture proteins, specifically antibodies [1]. The method of directed 
evolution used is called phage display and is a method of protein engineering in which 
antibodies are expressed on the surface of phages. The phages can then be screened for the 
antibodies with the most desirable binding properties. The gene for the ‘winning’ antibody is 
then sequenced and used to scale-up the production of this antibody to cure disease or 
develop biosensors [2]. Through this example, can see the importance of understanding 
protein function and how to produce proteins to perform specific functions. 
In order to effectively produce proteins, one must utilize the relationship between 
nucleic acids and proteins which is explained via the central dogma of molecular biology. 
DNA undergoes transcription in which it is used as a template to create mRNA. The 
information in mRNA is then translated into an amino acid sequence resulting in the protein 
that was encoded in the original DNA. Researchers typically utilize this by coercing living 
cells into producing their protein of interest. This is referred to as in vivo expression and 
commonly takes place in bacteria, yeast, insect, and Chinese hamster ovarian cells though 
other cell types are common as well. Each cell type requires a different expression vector and 
codon optimization specific to that organism (a codon is a sequence of 3 nucleotides that 
9 
code for one amino acid). The expression vector with the gene (sequence of DNA coding for 
a protein) of interest is inserted into the vector and transformed into the preferred host for 
expression. The host cells are then cultured and optimized for production of the specific 
protein. This is referred to as in vivo protein expression and is the common method to 
produce proteins. In vivo expression takes 2-3 days and is very useful when producing 
proteins in bulk quantities. Therefore, structural proteins such as keratin [3], reflectin [4], 
elastin [5], resilin [5], spider silk [5], etc. benefit from in vivo expression. While this method 
can be time consuming, it is still an effective way to study and engineer proteins. For 
instance, the Baker lab uses in silico methods to determine the relationship between the 
structure and function of proteins. They use this method to design new proteins, not found in 
nature, to perform a specific task, such as catalysis [6]. The Baker lab also uses this method 
for de novo protein design and expression using yeast display [7]. However, due to the time 
required to conduct in vivo expression, it may not be the best method to screen new active, 
non-binding proteins.  
There is an in vitro method of protein expression called cell-free protein synthesis 
(CFPS) that works much faster. As implied in the name cell-free, CFPS does not use living 
cells for protein expression but instead uses cell extract harvested from cells. This means that 
CFPS is essentially carried out in a test tube and has the benefit of being extremely modular 
[8]. However, cell-free systems do not produce as much protein as their in vivo counterparts, 
so it is best to use them for rapid prototyping. CFPS has also been used to express cytotoxic 
proteins that would kill the host cell [9,10] as well as difficult to express membrane proteins 
[11,12]. There are multiple cell types that can be used for CFPS but E. coli is the most 
common and the most productive [13]. A successful E. coli-based CFPS has three main 
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components required for protein expression: 1) a suitable energy mix, 2) a productive cell 
extract, and 3) a genetic template. This thesis explains how to produce each of these 
components for effective protein prototyping. Chapter 2 details the history and biological 
relevance of common energy systems and their components. It is a comprehensive literature 
review meant to educate newcomers to the field of E. coli-based CFPS. Chapter 3 outlines 
the methods used to manufacture productive cell extract from E. coli. It is a simple method 
designed to reduce batch-to-batch variation commonly encountered in extract preparation. 
The methods also allow workers to mass produce extract while spending less time at the 
bench. Chapter 4 provides a novel method of DNA amplification that allows from protein 
expression in as little as 24 hours. This method was designed to overcome the 2-3 day lead 
time experienced with expressing proteins in vivo. Using this method, we have been able to 
screen the activity of multiple proteins in less than 2 days using CFPS. 
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CHAPTER 2.    CELL-FREE ENERGY MIXTURES: ELUCIDATING THE 
HISTORY AND BIOCHEMICAL UTILTIY OF SUPPLEMENTS USED IN E. COLI 
CELL-FREE SYSTEMS 
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Abstract 
Cell-free protein synthesis (CFPS) has become an established biotechnology tool for 
rapid protein expression.  Over the past few decades many advances have elevated CFPS 
from a niche, low-efficiency system to one now capable of biomanufacturing custom 
proteins. Many research papers and reviews exist on the advances made in CFPS genetic 
template and cell extract preparation for use in E. coli systems. What is currently missing 
from the literature is a comprehensive review on the myriad of supplement recipes added to 
the CFPS reaction to support metabolism, transcription, and translation.  This list of 
supplements has changed over the years, with a general drive towards greater simplification. 
Herein we provide a comprehensive list of the supplements used in CFPS, tracing major 
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recipe classes as the field has evolved.  We also provide an in-depth analysis of the proposed 
biochemical purpose each supplement has in the reaction. This review reveals the 
significance of correct supplements on overall CFPS productivity; however, the large range 
of supplements accommodated by CFPS also shows an inherent flexibility in the CFPS 
reaction as well as additional room for optimization and recipe simplification. 
2.1 Introduction 
Cell-free protein synthesis (CFPS), also referred to as in vitro expression, is a robust 
method of protein expression that has the distinct advantage of being an open system 
allowing for manipulation of reaction conditions, manipulation of reactants, and direct 
monitoring of performance [1]. CFPS was first used in the 1960’s by Nirenberg and Matthaei 
to understand the genetic code [2] but has seen a recent revival in modern biotechnology 
applications.  CFPS has shown great utility as a tool for rapid protein screening through the 
production of antigens [3,4], virus-like particles [5], cytokines [6], antibodies [7,8], antibody 
analogs [4], antimicrobial peptides [4], membrane proteins [9–11], bacteriophages [12], 
phosphoproteins [13], cytotoxic onconase [14], and enzymes with metal cofactors [15,16]. 
Due to recent advances in synthetic gene circuit technology, CFPS is also becoming a more 
popular sensing platform [17]. These sensors have been used to detect Ebola [18], Zika virus 
[19], endocrine disruptors [20], and quorum sensing molecules [21]. These recent advances 
in cell-free technology, and its scalability, have enabled the founding of companies such as 
Sutro Biopharma and Greenlight Biosciences. There are many excellent reviews on the utility 
of CFPS and its history [1,17,22–27]; what is lacking in the literature, is a careful assessment 
of the many ingredients added to the cell extract in CFPS reactions. The three basic 
components of a CFPS reaction are cell extract, genetic template, and supplements to sustain 
the transcription and translation. This review highlights the ongoing evolution of 
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supplements used to support CFPS reactions. We focus solely on supplements for 
Escherichia coli based extract, as this cell chassis is the dominant cell type used for CFPS. 
This review will both acquaint new CFPS users with the import and necessity of the many 
supplements as well as highlight interesting trends in supplement use that could encourage 
further study by those already in the field. 
2.1.1 Process Flow Chart for CFPS 
Before embarking on a review of the many different components used for CFPS, we 
wish to present a unit operations [28] framework from which we can organize our discussion. 
At the basic level, a CFPS reaction consists of four unit operations: metabolism to support 
the recycling of energy rich reactants, transcription to convert template DNA to build-ready 
mRNA, translation to convert mRNA to protein, and post-translational modifications to 
augment nascent proteins (Fig 2.1). The metabolic operation runs in parallel, supporting the 
other three that operate in series (transcription→ translation→ post-translational 
modification) to produce the templated protein. Each unit operation has needed inputs that 
are supplied by the cell extract and supplemented by further additives. The biological 
necessity and extent of use for each supplement has changed drastically over the years, and 
thus has led to the utility of this review to highlight these trends. 
15 
 
Figure 2.1 - Unit operations of a cell-free protein reaction: DNA and metabolic additives 
must be added to initiate the reaction, the added DNA template is transcribed to mRNA that 
codes for the protein of interest, the mRNA is then translated via ribosome to protein, the 
expressed protein then undergoes any post-translational modifications that are supported by 
the system (eg. disulfide bonding, glycosylation). 
 
2.1.2 Genetic Template 
CFPS has great versatility in its ability to use various genetic templates. Most 
commonly used is a plasmid due to its stability against nucleases and similarity to in vitro 
expression. CFPS reactions also support linear templates supplied directly as PCR products. 
Genetically modified strains such as the BL21 Star (DE3) have been used to more effectively 
express protein from linear templates due to the removal of endogenous exonucleases. These 
advances have allowed rapid expression of proteins through the use of PCR products since it 
avoids time consuming cloning steps [29]. Recent work has also shown that rolling circle 
amplification (RCA) can be used on PCR products to generate large amounts of template 
from a small amount of synthesized linear template [30]. Immediately before starting the 
reaction, the genetic template is combined with the cell extract and supplements. 
Unfortunately, it is typical in CFPS literature to report DNA concentrations in ng/µL without 
reporting the DNA sequence. While concentrations tend to be in the nanomolar regime, it is 
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hard to determine typical range of concentrations without the aforementioned information. 
However, reporting a range of concentrations can be misleading since optimal template 
concentration varies based on the desired protein and should be determined empirically 
[31,32]. 
2.1.3 Cell-Free Extract 
The variations in cell free extract type and preparation methods are also not the 
subject of this review, however we will orient the reader briefly to their composition. The 
majority of CFPS extracts are derived from prokaryotic organisms, such as these E. coli cell 
lines BL21(DE3), BL21 Star (DE3) [33], Rosetta [34], Rosetta2 [35], KC6, KGK10. Strains 
with (DE3) in the name have been modified to carry the ƛDE3 so that the lacUV5 promoter 
controls the expression of T7 polymerase. This allows T7 promoter-based expression via 
induction of IPTG. The BL21(DE3) and BL21(DE3) Star strains are engineered from B834 
and lack both the Lon and and OmpT proteases, which enhances recombinant protein yield. 
BL21 Star (DE3) has a mutated RNaseE gene (rne131) impairing its ability to cleave mRNA. 
This enables BL21 Star (DE3) to use linear expression templates (LETs) for protein synthesis 
without the supplementation of GamS protein [36]. The Rosetta strains are BL21 derivatives 
that can express the codons AGG, AUA, AGA, CCC, CUA, and GGA on a pRARE plasmid. 
The Rosetta2 expresses the six aforementioned codons as well as CGG. The KC6 strain was 
developed to stop cysteine degradation by removal of glutamate-cysteine ligase (gene gshA). 
KC6 incorporates gshA deletion as well as previous modifications to stabilize arginine, 
serine, and tryptophan [37]. KC6 has been used to more effectively express disulfide bonded 
proteins [3]. KGK10 is a modified version of the KC6 strain without the glutathione 
reductase (Gor) gene and an added hemagglutinin tag on the thioredoxin reductase (TrxB) 
gene. The Gor and TrxB genes are both responsible for reducing disulfide bonds. KGK10 
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was engineered to produce disulfide bonded proteins when using glucose as the primary 
source of energy, and reduce the amount of iodoacetamide required to pretreat the extract 
[38]. There have been recent papers that detail optimized preparation methods for small [33] 
and large scale E. coli extract [39]. There has also been work detailing different cell 
disruption methods such as: bead milling [40], bead vortexing [41], French press [42], 
impinge homogenization [43], sonication [33], a combination of lysozymes and freeze-thaw 
cycles (Fujiwara and Doi, 2016), and autolysis induced via freeze-thaw cycling [45]. 
Researchers also have the option of avoiding extract preparation entirely. This can be done 
by using commercial CFPS kits or by using the PURExpress kit. The PURExpress kit does 
not involve a whole cell extract, rather it is made up of the components needed for protein 
synthesis that have been individually expressed and purified [46]. An additional option for 
extract preparation, post lysis, is that of lyophilization, or freeze-drying. Lyophilized extracts 
have recently become popular due to their robust ability to maintain expression at elevated 
storage temperatures allowing the portable manufacture of therapeutics, paper-based gene 
networks, and paper-based sensors [4,39,47–49]. 
E. coli is not the only cell chassis used to produce extract for CFPS. Eukaryotic cells 
such as protozoa [50], yeast [51], wheat germ [52], tobacco BƔ-2 [53], insect cell [54], rabbit 
reticulocyte [55], Chinese hamster ovarian (CHO) cells [56], and human cells [57] have also 
shown to be viable cell-free systems. The major advantage of eukaryotic cells is the ability to 
perform advanced modifications post-translation, such as glycosylation. However, these 
eukaryotic systems tend to require laborious extract preparation and have high cultivation 
costs. The yield in E. coli-based systems currently outpaces that of eukaryotic systems but 
this is not true for all cases and can be heavily dependent on the expressed protein [24]. For 
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protein yield comparison, a high yield streptomyces system recently produced 282±8 µg/mL 
of eGFP in 48 hr [58] while a high yield E. coli system can produce 2.3 mg/mL of deGFP in 
10 hr [59]. 
The cell extract preparation process commonly introduces a few salt supplements. 
These are present in the buffers used to wash the cells and resuspend for homogenization. 
The most common buffer is generally referred to as S30 and it is composed of 50 mM Tris-
HCl, 60 mM potassium glutamate, 14 mM magnesium acetate, and 2 mM dithiothreitol 
(DTT) [33,41]. However, each extract is slightly different. It was noted early on that the 
concentration of magnesium should be optimized for each batch of extract in order improve 
expression [60]. Conditions can be further improved by optimizing the final potassium 
concentration of the reaction as well [31]. Some of these compounds are also listed in the 
additives portion of this paper. However, those listed are added in addition to what is already 
present in the buffer. 
2.1.4 Reaction Conditions 
Before reviewing supplements, we must also mention briefly the variations in CFPS 
reaction conditions. Reactions are typically carried out in batch mode using well plates or 
microcentrifuge tubes. Reactions are typically carried out in relatively small volumes of 10 - 
50 µL. However, CFPS has been shown to result in similar protein concentrations in reaction 
volumes up to 100 L [6]. It may be important note that this scale-up study used the Cytomim 
system (covered herein) which relies on oxidative phosphorylation, therefore oxygen 
transport had to be considered [61]. This is not the case for other energy systems. There has 
also been some effort to design continuous CFPS systems in which exhausted metabolites are 
removed and replaced with fresh additives. This research was originally conducted when 
batch CFPS activity was very short (~1 hour) by using fed-batch reactors to replenish 
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depleted substrates [62,63]. More recent developments have seen CFPS carried out in 
continuous exchange vessels [64] and in lab on a chip microarrays [65] in order to improve 
efficiency. There has also been a combination of a continuous exchange membrane in a 
microfluidic device to facilitate point of care production for therapeutic proteins [66]. CFPS 
reactions are typically carried out in batch, plug flow, or continuous exchange format at 
37°C. Batch reactions do not require continuous stirring, unless gas exchange is necessary. 
However, improvements in yield have been observed when using a reaction vessel that limits 
diffusion distance though this may also be due to the lipid membranes enclosing the reactions 
[67,68]. Yield increases have also been observed in small-scale plug flow systems [66] and 
suggest that CFPS may be diffusion limited. Continuous exchange methods tend to use 
semipermeable membranes with gentle agitation (stirring) to remove metabolic waste while 
supplying the system with fresh energy substrates. These have resulted in increased yield 
while using the same amount of cell extract, but they require a continuous supply of energy 
substrates [54,62,64,66,69,70]. These conditions tend to be the status quo until one desires to 
express disulfide bonded proteins. Proteins with disulfide bonds are typically expressed at 
lower temperatures, such as 30°C [6,71]. While temperatures of 37°C and 30°C are the most 
common, it should be noted that the optimum temperature of expression can vary depending 
on the protein of interest and should be determined empirically [31]. 
2.1.5 Measuring Protein Yield 
It must be acknowledged here that comparisons between studies is greatly 
confounded by the use of many different reporter proteins expressed and different methods of 
protein quantification. Popular fluorescent proteins tend to be derivatives of GFP such as 
sfGFP, eGFP, deGFP, and others due to the ability to take live measurements for kinetic 
studies. Popular bioluminescent proteins such as firefly (fLuc) and renilla (rLuc) luciferases 
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have also used due to their high signal to noise ratio. The fluorescence or luminescence from 
these proteins must then be correlated with concentration via a calibration curve created 
using a quantification method. These methods include reading the absorbance at 280 nm [7] 
which uses the Beer-Lambert law to provide concentration if the extinction coefficient is 
known, the incorporation of radiolabeled leucine in the expressed protein which is then 
precipitated by trichloroacetic acid and analyzed with a scintillation counter [61], and 
Bradford type assays such as the Pierce™ 660 nm assay [39]. Each method has their 
advantages and disadvantages. Currently, the incorporation of 14C-leucine is the most 
popular method for low mass quantification of expressed protein from CFPS. It is also 
common to neglect reporting the protein yield in favor of reporting relative activity as a 
percentage difference for optimization studies. The total protein content of cell extract can 
also be determined and is typically carried out with a standard Bradford assay. 
2.2 Results and Discussion 
2.2.1 Historical Evolution of Supplement Classes Based on Increased Biochemical 
Understanding 
Before detailing each of the additives individually and classifying their role in the 
unit operation framework, the major historical classes of supplement recipes are presented. It 
is important to note that all phosphorylated energy sources cause inorganic phosphate to 
accumulate in the reaction. It has been reported that a critical concentration of inorganic 
phosphate (40-50 mM) will decrease magnesium ion concentration and halt protein synthesis 
[72]. Much progress in the field of CFPS supplementation has been made in an effort to 
recycle accumulated inorganic phosphates. 
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2.2.1.1 Historic CFPS supplements 
In the formative years of CFPS, the systems were all translation based and used 
mRNA as a genetic template. The first successful example of this was reported from the 
Zamecnik lab in 1957. The researchers were able to show that the ribosome is responsible for 
peptide synthesis and that this process requires ATP, GTP, and tRNA [73]. Following this 
discovery, Matthaei and Nirenberg used CFPS to help understand the genetic coding 
mechanism of proteins [2]. The cell-free reaction supplements can be seen in Table 2.1. In 
1967 Zubay and DeVries conducted the first cell-free transcription/translation reaction using 
ɸ80 dlac DNA [74]. In 1973, Zubay published methods for preparing a CFPS system using 
the reagents listed in Table 2.1 [60]. In 1984, Pratt published methods for implementing a 
CFPS system that would become a common a starting point for much future research [75]. 
The Spirin lab introduced a new energy source (acetylphosphate) in 1995 but this alternative 
energy source never gained widespread use. Using this system, they produced an MS2 
bacteriophage coat protein but reported in yield in terms of 14C leucine incorporation [76]. 
In 1996, Kim et al. reportedly surpassed previous expression levels by both batch and 
continuous flow systems with a yield of 0.4 mg/mL [77] by optimizing the concentrations of 
PEP and PEG 7500. Details for the recipes that could be accessed are available in Table 2.1. 
2.2.1.2 PANOx 
The PANOx energy system was one of the early attempts to prolong CFPS by 
introducing cofactors that should regenerate ATP. Developed in 2001 by the Swartz lab, the 
term PANOx is an acronym for phosphoenolpyruvate (PEP), amino acids, nicotinamide 
dinucleotide (NAD), and oxalic acid [78]. Prior to the development of the PANOx system, 
secondary energy sources such as acetyl phosphate, creatine phosphate (CP), and PEP had 
been established in CFPS, as shown in Table 2.1. These energy substrates were used in 
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tandem with the enzymes acetate kinase, creatine kinase, and pyruvate kinase to catalyze 
transfer of phosphate bonds from the energy sources to ADP. The PANOx system was 
developed to prolong cell-free reactions by enabling ATP regeneration from PEP without the 
addition of exogenous enzymes and reported a 168 µg/mL yield of CAT [78]. The 
components and concentrations levels can be seen in Table 2.1. 
2.2.1.3 PANOx-SP 
The PANOx-SP system was developed in 2003 (published in 2004) by the Swartz 
group as an improvement over the PANOx system. The term PANOx-SP is an acronym for 
PEP, amino acids, NAD, oxalic acid, spermidine, and putrescine. However, initial tests with 
the PANOx-SP system showed no advantage over the traditional PANOx system [79]. This 
was soon remedied with slight modifications to the original recipe, such as the addition of a 
HEPES/KOH buffer. At this same time, it was shown that the system could be modified to 
work with glucose instead of PEP, rNMPs instead of rNTPs, Bis-Tris instead of HEPES, and 
the removal of oxalate. This glucose/NMP system significantly reduced the reagent cost [80]. 
When allowed to go to completion (20 hr), the PANOx-SP system has been shown to 
produce ~1 mg/mL sfGFP [33]. The most popular iteration of the PANOx-SP is seen in 
Table 2.1. Variations of this system are commonly used the Swartz, Jewett, and Bundy labs 
[81–83]. 
2.2.1.4 Cytomim 
The Cytomim system was designed in 2003 by the Swartz group to mimic the in vivo 
conditions found in Escherichia coli and initially produced ~550 ug/mL of CAT[79]. It is 
able to provide a stable energy supply for cell-free protein synthesis with the removed of 
negative side effects such as the accumulation of inorganic phosphates, large drops in pH, the 
addition of exogenous enzyme, or the need for pricey phosphorylated energy sources [79]). 
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Modifications have since been made to the Cytomim system to make it more productive and 
cost efficient by removing unnecessary components [7,84]. However, the Cytomim system 
relies heavily on the tricarboxylic acid (TCA) cycle (also called the citric cycle) (see Fig 2.3), 
so cells used for extract production in the Cytomim system must be grown in glucose rich 
media, such as 2x YTPG [63,84]. Data suggests that the Cytomim system operates on 
oxidative phosphorylation (Fig 2.4) and requires sufficient gas exchange for continuous 
access to oxygen [84]. During Sutro’s optimization study, they reported a yield of 1.3-1.4 
mg/mL of TurboGFP using their modified Cytomim system [7]. The typical components of 
this supplement recipe are shown in Table 2.1. 
2.2.1.5 Creatine phosphate 
The main source of energy in this system is creatine phosphate (CP). The CP system 
is not endogenous to E. coli and was published in 1999 by the Yokoyama lab. The original 
system was developed as an alternative to the PEP and acetyl phosphate (AP) systems used at 
the time and provided an increase in production [85]. It was shown that increasing the initial 
concentration of CP increased protein yield while increasing the initial PEP concentration 
reduced protein synthesis. The yields of CAT and GFP were improved to 1.3 and 1.2 mg/mL 
respectively after 2 hr of incubation [72]. This system was also cost optimized for more 
economical protein synthesis [42]. Components of a CP system recipe are listed in Table 2.1. 
2.2.1.6 3-Phosphoglycerate 
The 3-phosphoglycerate (3-PGA) system was developed in the Chatterjee lab and 
published in 2004. This system uses 3-PGA as an energy source and was developed as an 
alternative to PEP and CP based systems due to non-specific degradation by phosphatases 
that had previously been observed [78,86]. The 3-PGA system produced more protein than 
the standard systems of the time (>1 mg/mL GFP assayed via fluorescence) and it was 
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believed that this was due to 3-PGA being more stable in E. coli extract than PEP or CP [34]. 
Typical reagents are again listed in Table 2.1. This system is responsible for the highest batch 
yield of protein seen to date (2.3 mg/mL) after 10 hr of incubation and variations are used in 
the Noireaux and Collins labs [4,59]. 
2.2.1.7 The PURE System 
The PURE system is essentially a variation of the creatine phosphate system so the 
components are not addressed in Table 2.1. However, it is unique because it does not use 
traditional cell-free extract. The methods detailing the construction of the PURE system were 
published in 2001 and describe how to express and purify all necessary machinery in vivo. 
The system is broken into two mixes: 1) the creatine phosphate energy mix and 2) a purified 
factor mix containing ribosomes, translation factors, and enzymes. This system was able to 
express more than 100 µg/mL of GFP after 1 hr of incubation [46]. The PURE system can be 
expressed in-house or purchased from NEB. This system has been used to perform various 
CFPS experiments because it has the advantage of eliminating any side reactions that could 
interfere with protein synthesis [87–90]. 
2.2.1.8 Optimization studies 
It is important to mention that there have been optimization studies conducted to 
determine the most effective energy substrates. However, each of these studies limit their 
experiments to a single energy system. In 2011 the Karlsson group set out to improve amino 
acid incorporation by using a series of designed experiments to optimize the CP system. 
Using a central composite design (CCD) they found that yield could be appreciably increased 
by optimizing serine and glutamine, as well as adding 3 ketoacids that take part in the citric 
acid cycle. Expression levels of wtGFP went from 190 µg/mL to 400 µg/mL upon 
implementing the optimized conditions [91]. Since then, a group from Japan set out to mimic 
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the intracellular environment by increasing molecular crowding in CFPS. While this was not 
an optimization study per se, they were able to individually remove HEPES buffer, amino 
acids, or rNTPs from their CP system with no adverse effects on protein expression. The 
reported concentration of sfGFP was 3.2 µM which should correspond to ~85 µg/mL [92]. 
Another optimization attempt was carried out in 2013 using PANOx-SP system. Using sGFP 
as a reporter, the group explored suitable concentrations of DTT, PEG of varying molecular 
weight, NH4+, plasmid template concentration, Mg2+, PEP, and NTPs. They found that each 
of these components has an optimal range and observed that Mg2+ could be optimized with 
respect to NTPs as well as PEP. The final yield of sGFP with optimized conditions was 720-
900 µg/mL [93]. The most recent optimization study at the time of this writing is a 
comprehensive work by Sutro Biopharma. Sutro was able to eliminate 7 supplements from 
the Cytomim system while observing similar, or improved, yields of 19 different proteins 
(e.g. 1.3-1.4 mg/mL TurboGFP) [7]. 
2.2.2 Metabolism 
The understanding of cell-free metabolism has changed much over the years. As can 
be seen in Table 2.1, many systems rely on dephosphorylation for energy. This method relies 
on the removal of a phosphate group from PEP, catalyzed by pyruvate kinase, to ADP. This 
process results in 1 molecule of pyruvate and 1 molecule of PEP. A diagram of the glycolysis 
cycle with the addition of maltose can be seen in Fig 2.2. However, it wasn’t until the 
creation of the Cytomim system that researchers realized that the TCA cycle was still intact 
(Fig 2.3) and oxidative phosphorylation was occurring (Fig 2.4). Since then, supplement 
recipes have been developed that support these metabolic networks. Buffers, salts, glycolytic 
substrates, and co-factors are added to support these central metabolic networks which in turn 
drive the transcription, translation, and post-translation modification unit operations. 
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Figure 2.2 – A flowchart representing the locations of various glycolytic intermediates in the 
glycolysis pathway. It also shows the production and consumption of ATP. This work 
suggests supplementing maltose as a method to recycle inorganic phosphates (iP) and 
prolong the reaction. Some glycolytic intermediates are left out for simplicity. This figure has 
been adapted from [22]. 
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Figure 2.3 – Schematic of the citric acid cycle, also known as tricarboxylic acid (TCA) 
cycle. This diagram shows the pathway used by glutamate to activate the TCA cycle in the 
Cytomim system (Swartz 2008). It also shows the positions of malic acid (malate), succinic 
acid (succinate), and 2-oxoglutaric acid (⍺-ketoglutarate) added by the Karlsson group 
(Pedersen 2011). Copyright Eleni Theodosiou, Oliver Frick, Bruno Bühler, and Andreas 
Schmid. Metabolic network capacity of Escherichia coli for Krebs cycle-dependent proline 
hydroxylation. BioMed Central. Reproduced and altered under creative commons license 
from [26]. 
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Figure 2.4 – Schematic of the energy pathway used by the Cytomim system. The main 
source of energy, glutamate (GLU), is used to produce reducing equivalents via the TCA. 
Oxidative phosphorylation is fueled by the produced NADH. Membrane particles still 
present in the extract support respiration and provide ATP. F1F0-ATPase enzyme complexes 
are denoted with an * (ETC, electron transport chain; PMF, proton motive force; 𝛼KG, 
alpha-ketoglutarate; SUC, succinate; MAL, malate; PYR, pyruvate; OAC, acetate; OAA, 
oxaloacetate; ASP, aspartic acid; Pi, inorganic phosphate; TFs, translation factors; aa-tRNAs, 
aminoacylated-tRNAs). Michael C Jewett, Kara A Calhoun, Alexei Voloshin, Jessica J Wuu, 
and James R Swartz: An integrated cell-free metabolic platform for protein production and 
synthetic biology. Molecular Systems Biology. 2008. Volume 4. Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission [15]. 
 
2.2.2.1 Buffers 
During vegetative growth, bacteria use various mechanisms to maintain cytoplasmic 
pH (active H+ transport, metabolic reactions, and through passive physiological adaptations).  
In general, these mechanisms of maintaining physiological pH are facilitated with the 
use of the cellular membrane, or transcription regulation. The current framework of CFPS 
assumes that both the cellular membrane and the genome are disrupted to a degree where 
they can no longer maintain physiological pH. Therefore, a rudimentary approach is taken to 
maintain the pH as well as ionic strength in a static way by supplying a buffer of choice. Due 
to the fact that biological interactions of buffers are largely unpredictable in convoluted 
systems, in most cases the type of buffer, pH and ionic strength of the solution are optimized 
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empirically based on the following criteria: 1) pKa values - ability to maintain desired pH, 2) 
Solubility - buffers should not accumulate in the insoluble fractions, 3) minimal salt effects - 
buffer solutions should not significantly impact the ionic strength of the solution, and 4) inert 
to cellular metabolism - the buffer of choice should not impact the native processes of the 
cell [94]. 
HEPES is a very common buffer used in CFPS with a pKa of 7.5 and useful pH range 
of 6.8 to 8.2. The desired pH range is achieved through titration with KOH to achieve the 
desired pH. It is the buffer of choice for most energy systems [4,48,82]. Tris-Bis is used to 
buffer systems that experience large pH drops below the optimal for protein synthesis such as 
those energized by glucose [81,95]. Tris-Bis has a pKa of 6.46 and useful pH range of 5.8 to 
7.2. Potassium phosphate was originally added to alleviate phosphate limitation when 
glucose was used instead of a phosphorylated energy source [80]. However, it was not 
determined whether this extra phosphate improved oxidative phosphorylation, inhibited 
phosphatase attacks, or both [84]. Potassium phosphate has a pKa of 7.21. It is important to 
understand the buffering capacity of the chosen buffer since pH has significant effect on 
protein yield. Maximum protein expression has been reported to occur when the initial pH of 
the reaction is 6.8 [79]. However, poor buffer and energy source matching will allow the pH 
to drop below suitable expression levels (<6.2) [95]. 
2.2.2.2 Ions 
In order to easily explain the biological role of various ionic compounds, we split 
them into cations and anions. However, it is important to note that these compounds 
contribute to the ionic strength of the CFPS reaction which has a significant influence on 
electrostatic interactions [96,97]. Ionic strength is typically defined as the total concentration 
of electrolytes in a solution. However, biological systems are complex due to ion-ion and 
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ion-biomolecule interactions. Because of this, it might be best to think of it in terms of 
effective ion concentration, or thermodynamic activity. While this is very hard to measure, 
recent advances may improve our ability to do so [98]. Simple manipulations of ionic 
strength have been shown to affect intrinsically disordered proteins [99], enzyme activity 
[100], protein aggregation [101], phase separations [102], protein-nucleic acid interaction 
[103], protein solubility [104], and antibody-antigen association [105]. Thus, careless 
manipulation of ion concentration in CFPS could inhibit the production of functional 
proteins. 
Significant cations for CFPS include potassium (K+), magnesium (Mg2+), and 
ammonium (NH4+). Potassium plays a role in maintaining the proton motive force (PMF) 
across the vesicles that are formed during the process of cell disruption [94]. Under stress-
free conditions, in vivo K+ concentrations range from 60 to 150 mM [106–108]. High K+ 
concentrations (0.5 to 1 M) can cause dissociation of ribosomes in vitro [108,109] due to 
competitive binding with Mg2+ [108,110]. Potassium is also used as a signaling molecule 
that communicates various changes in the extracellular environment. It is hypothesized that 
due to the process of cell disruption, intracellular concentrations of potassium decrease, and 
therefore, some is supplemented to reinstall ionic homeostasis [111]. Magnesium is involved 
in many steps of protein synthesis including the aminoacylation of tRNA [112], formation of 
the ternary initiation complex [113], ribosomal complex maintenance [114]. More 
specifically, Mg2+ concentrations above 15 mM force ribosomal subunits to associate into 
70S ribosomes [108,115,116] while concentrations of 1 mM and below causes the 
dissociation, and eventual unfolding of 70S ribosomes [108,117,118]. In systems containing 
only Mg2+ and monovalent cations (i.e. K+ and NH4+), the addition of polyamines, 
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particularly spermidine (2 mM), is required to keep ribosomes from deactivating at Mg2+ 
concentrations below 10 mM [108,119–123]. Magnesium also acts as a cofactor in many 
enzymes and ribozymes involved in the cleavage of phosphate esters and the transfer of 
phosphate groups [124]. Though expression has been carried out without the addition of 
exogenous magnesium [76], a more recent study showed that it is an indispensable 
supplement [92] and it has been suggested that magnesium should be optimized for each 
batch of cell extract [60]. Ammonium has been a historical staple to CFPS reactions (as seen 
in Table 2.1) and has been viewed as an excellent source of nitrogen for bacteria [125]. 
However, it is not clear whether the addition of exogenous ammonium is necessary for 
expression. The optimization study conducted by Sutro found no significant effect on 
expression (<10%) when removing it from their reaction [7].  
Anions (counterions) are used to balance the charge of necessary cations and have 
also been shown to directly contribute to CFPS efficiency; these include acetate, glutamate, 
and oxalate. Acetate was originally added as a counterion for potassium, magnesium, and 
ammonium. It is already present in the reaction since it is part of the buffer used in extract 
preparation. However, acetate accumulation can be detrimental to protein expression since it 
causes a drop in pH. This is especially the case when the primary source of energy is glucose 
[79]. It has also been shown that glutamate promotes stronger protein-nucleic acid 
interactions than acetate [126]. As seen in Table 2.1, acetate is no longer as common as 
glutamate in CFPS recipes. Glutamate was originally added as a counterion to potassium but 
has proven to be adequate for ATP regeneration via the oxidative phosphorylation pathway 
[7]. In fact, glutamate alone can be used as the primary energy system due to its ability to 
form reducing equivalents. It is hypothesized that glutamate enters the citric acid cycle as 
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alpha-ketoglutarate which is formed by glutamate dehydrogenase or aspartate 
aminotransferase [84]. Other factors that contribute to the addition of glutamate include its 
dominant presence when E. coli undergo osmotic stress and its ability to provide more 
favorable protein-nucleic acid interactions than acetate [126]. When added as potassium 
glutamate, it has also been shown to stabilized folded proteins and the ribosomal protein 
domain NTL9 [127]. Oxalate can be added in the form of either sodium oxalate or potassium 
oxalate. Oxalic acid has been shown to impair protein yields and have a negative impact on 
ATP concentrations when early glycolytic intermediates such as glucose are used [79,81]. 
However, it is essential in PEP based systems that do not use early glycolytic intermediates 
since it inhibits PEP synthase, thereby inhibiting gluconeogenesis, and eliminates a futile 
cycle that wastes ATP [7]. 
2.2.2.3 Glycolysis 
Phosphorylated glycolytic intermediates are by far the most popular sources of energy 
for CFPS systems. However, each phosphorylated intermediate will contribute to the buildup 
of inorganic phosphate. Phosphoenolpyruvate (PEP) has historically been one of the more 
popular sources of energy for the cell-free system (PANOx and PANOx-SP) [79]. Pyruvate 
was originally added as a cheap alternative to PEP in the form of sodium pyruvate but 
resulted in lower protein yields [78]. It has been used as a source of energy in the Cytomim 
system. However, recent data shows that the Cytomim system works without Pyruvate as 
long as it incorporates increased potassium glutamate [7]. This can be attributed to the fact 
that free glutamate enters TCA cycle in form of alpha-ketoglutarate, thus facilitating 
oxidative phosphorylation [84]. Creatine Phosphate (CP) is not endogenous to E. coli but was 
added as an alternative energy source to PEP. Creatine kinase is used in conjunction with CP. 
Creatine kinase can be added to the reaction or overexpressed during cell growth [5] but it is 
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not endogenous to E. coli [31]. The primary role of creatine kinase is to facilitate substrate 
level phosphorylation of ADP using CP as a substrate. 3-Phosphoglyceric acid (3-PGA) can 
be used as a reduced source of electrons entering the glycolysis cycle at the 3-PGA kinase 
step. 3-PGA was originally added to reduce the effect of phosphatases by keeping the PEP 
concentration low, thereby prolonging the reaction [34]. 3-PGA has been successfully used in 
conjunction with maltose to yield large quantities of protein [31]. Glucose 6-phosphate (G6P) 
like glucose, was added for its competitive price and ability to generate ATP (3 mole-
ATP/mole-G6P) [78]. Initial tests with G6P showed a drop in pH below the appropriate 
range for protein synthesis within the first 20 minutes. However, this was remedied by 
replacing the HEPES buffer with Bis-Tris. This supported the hypothesis that any glycolytic 
intermediate could be used for CFPS [95]. Fructose-1,6-bisphosphate (FBP) is another early 
glycolytic intermediate that has shown to be effective in CFPS. In 2007, FBP was shown to 
outperform other glycolytic intermediates tested in the study while maintaining a low reagent 
cost. However, this energy source has yet to be adopted widely in the literature [128].  
Saccharides are generally not used as an energy source in CFPS systems. However, 
multiple studies have been conducted using saccharides to prolong the reaction 
[59,78,129,130]. Glucose was originally added to reduce the cost of energy sources and 
provide better ATP generation (2 mole-ATP/mole-glucose). Initial attempts at glucose 
metabolism resulted in virtually zero protein production. This was improved by stabilizing 
the pH of glucose containing reactions with Bis-Tris (pKa ~6.5), adding dibasic phosphate 
with a pH of 7.2, and removing sodium oxalate. Glucose initially showed potential by 
prolonging protein production in the absence of a phosphate containing energy source. 
However, this had a negative impact on the initial rate of protein production [95]. Since then, 
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Kim et al. has shown a significant yield in protein synthesis using glucose, NAD, and CoA to 
supplement the traditional CP system. This dual energy source also delayed the accumulation 
of inorganic phosphates [129]. Glucose has also been shown to provide a source of carbon 
for de novo amino acid synthesis [81]. Maltose has been shown to improve protein synthesis 
by recycling inorganic phosphate and regenerating ATP. Optimization of maltose 
concentration in the study showed that it works best at lower concentrations (12-15 mM) 
[59]. Maltodextrin has been shown to play a role in the recycling of inorganic phosphate and 
regeneration of ATP but was originally only used in conjunction with two exogenous 
enzymes (maltodextrin phosphorylase and phosphoglucomutase) [131]. Upon further 
investigation, it was shown that neither enzyme improves protein synthesis when using 
maltodextrin. This suggests that the necessary enzymes are already present in the cell extract. 
Maltodextrin has also been shown to be more effective at higher concentrations than maltose 
(20-25 mM) [59]. Starch has also been used to slowly release glucose. It was added as a way 
to avoid the detrimental pH effects caused by using glucose directly. When compared to 
previous methods that used glucose, starch alleviated the pH drop and prolonged CFPS 
[130]. 
2.2.2.4 Cofactors 
While cofactors are not emphasized as much as energy-supplying, glycolytic 
intermediates, they are still necessary to mediate enzymatic activity. The two popular 
cofactors in CFPS reactions are NAD and CoA. NAD allows for the condensation of 
pyruvate and CoA to form acetyl-CoA. During this reaction, NAD is reduced to NADH. 
NAD was introduced in the PANOx system to take advantage of this reaction and regenerate 
ATP via glycolysis [78]. NAD is also a very important component in both the citric acid 
cycle and oxidative phosphorylation. However, until the implementation of the Cytomim 
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system these pathways were thought to be absent in CFPS [84]. The optimization study by 
Sutro shows that NAD may be present at high enough levels for the Cytomim system without 
supplementation since there was no appreciable difference in expression upon its removal 
[7]. CoA was added to the PANOx system, along with NAD, to regenerate ATP [78]. CoA is 
a co-substrate that in the presence of NAD is used by the pyruvate dehydrogenase complex to 
form acetyl-CoA through the oxidative decarboxylation of pyruvate [7]. CoA is also a major 
player in oxidative phosphorylation and TCA cycle which was shown to be active in CFPS 
[84]. Along with NAD, the removal of CoA from Sutro’s Cytomim system showed no 
appreciable decline in protein expression [7]. 
2.2.3 Transcription 
The first unit operation that metabolism supports in a cell-free system is transcription, 
the process by which a gene encoded in the genetic template (DNA) is copied into messenger 
RNA for use by the ribosomes. In this step, the building blocks of RNA synthesis are 
ribonucleoside triphosphates (rNTPs), specifically the ribonucleotides adenosine, cytosine, 
guanosine, and uridine bearing three phosphate groups. These rNTPs can also be used as 
energy stores, mainly ATP. RNA synthesis requires the presence of an RNA polymerase and 
a DNA template. Ribonucleoside monophosphates (rNMPs) were first shown to be effective 
nucleotides for protein synthesis in the PANOx-SP suggesting that the necessary enzymes 
(adenylate, guanylate, cytidylate, and uridylate kinases) required to produce NTPs from 
NMPs are still present [80]. NMPs were also shown to be effective in the Cytomim system 
though the overall amount of protein produced is less but the cost per mg of protein is 
significantly reduced [84]. Since then, it has been shown that CFPS can work in the absence 
of NTPs, and NMPs [92]. RNA polymerase catalyzes RNA synthesis; however, it is common 
practice to use a DNA template that contains a T7 promoter. Exogenous polymerases can be 
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added as part of the reaction, or, in the case of T7 polymerase, can be induced during cell 
growth by the addition of IPTG to the cell culture [39,43,132]. However, T7 RNA 
polymerase is only required when the desired gene is behind a T7 promoter. Some groups 
have repressed their desired gene via other methods for use in synthetic gene circuits 
[18,133]. IPTG can be added to the CFPS reaction. However, IPTG is typically used to 
overexpress T7RNAP during cell growth. Cyclic adenosine monophosphate (cAMP) binds to 
cAMP receptor protein (CRP) and forms a complex that binds upstream of the lac promoter 
which supports the binding of RNA polymerase to the adjacent promoter and begin 
transcription of the lac operon. It also activates multiple protein kinases [134]. cAMP also 
plays a role in regulating glycolysis by activating the expression of catabolic promoters while 
inhibiting anabolic promoters. It is necessary to restructure carbon catabolism once the 
preferred carbon source is no longer present [135].  
Macromolecular crowding agents are sometimes used to mimic the in vivo 
environment [136]. The most common crowding agent used in CFPS is polyethylene glycol 
(PEG) because it is known to improve the accessibility to other compounds by binding water 
[93]. It has also been shown to improve self-assembly by lower the critical concentration 
[137,138]. PEG of various molecular weights can be added to CFPS, but the characteristics 
change with varying molecular weight [139]. PEG has been shown boost transcription by 
increasing mRNA production. This increased transcription has been shown to come at a cost 
of reduced translation when using PEG 8000 [140]. However, PEG has recently been 
reported to induce a 3-fold increase in deGFP yield while increasing the synthesis of phages 
by a factor of 4000 [12]. PEG 8000 has been used to simulate macromolecular crowding 
since cell-free extract is much more dilute (20-30 times) than the cytoplasm of a cell. 
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Measurements have shown that cell-free extract contains 9.5-10 mg/mL of protein while the 
cytoplasm has 250-300 mg/mL [12]. In a systematic study on the effect of varying the 
molecular weight of PEG in a CFPS system, it was observed that PEG (MW 200-8000 except 
for 400) could improve sGFP fluorescence 10-20%. It was also observed that the addition of 
PEG 10000 caused reaction components to precipitate. The most effective concentration 
range for PEG was 2-3% w/v [93]. 
Gam Protein is from phage lambda and inhibits RecBCD (Exo V) which inhibits the 
in vitro degradation of Linear DNA. The addition of gam protein can improve CFPS yields in 
BL21(DE3) to levels competitive with plasmid templates [34]. It has been shown that gam 
protein is necessary since protein synthesis from linear PCR products is negligible in the 
absence of gam [12]. However, gam is not necessary when using BL21(DE3) Star due to the 
mutation. 
2.2.4 Translation 
The second unit operation that metabolism supports in a CFPS system is translation, 
the process by which the mRNA information is converted into an amino acid sequence (Fig 
2.1). Transfer RNA (tRNA) serves as the physical link between the mRNA and the amino 
acids of the expressed protein. E. coli total tRNA has historically been added to supplement 
endogenous tRNA. However, the optimization study conducted by Sutro showed increased 
expression without the addition of exogenous tRNA. This could be explained by an 
abundance of operative tRNA still present in the cell extract [7]. Folinic acid is a long-time 
supplement (Table 2.1) that is a precursor for formylmethionine (fMet) synthesis. While the 
presence of fMet is required for prokaryotic translation initiation, the Sutro optimization 
study showed increased yields when folinic acid was omitted from the reaction. A possible 
explanation for this is that the extract still contains endogenous fMet or its precursors [7]. 
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Amino acids are an obvious inclusion in any CFPS system but not all are incorporated into 
the final protein. Not much has been done to understand this issue, but a study in 2011 was 
able to increase amino acid incorporation and discovered that optimized concentrations of 
serine and glutamine can lead to a significant increase in expression in the CP system [91]. It 
is also common to add isotopically labeled amino for protein quantification, but these can 
also be added for NMR studies [91]. Non-natural amino acids can also be incorporated to 
perform interesting site-specific chemistry or change the material properties [141,142].  
Polyamines, spermidine and putrescine, are also commonly added due to their 
involvement in RNA stabilization and gene expression. Spermidine is a polyamine that was 
incorporated as part of the PANOx-SP system to help mimic the native cytoplasmic 
environment [79]. Spermidine has been shown to cause a structural change in mRNA by 
binding near the Shine-Dalgarno (SD) sequence. This structural change facilitates binding to 
the 30 S ribosomal subunit [143]. Spermidine has also been shown to induce another change 
in mRNA that stimulates Met-tRNAf binding to 40 S ribosomal subunits [144]. Spermidine 
is now common among added supplements and was recently optimized by Sutro using the 
Cytomim system [7]. Putrescine was added to mimic the native cytoplasm [79]. Large 
amounts of putrescine can be found in live E. coli cells and putrescine can be catalyzed to 
form spermidine. However, putrescine does no interact with macromolecules as strongly as 
spermidine, but it is thought to be a regulator of gene expression [143]. Sutro’s optimization 
study found the best protein yields occurred when putrescine was omitted from the reaction. 
This may be attributed to the fact that gene regulation and cell viability are not relevant for in 
vitro expression [7]. 
39 
2.2.5 Post Translation 
The final unit operation in CFPS is the implementation of post translational 
modifications. This unit operation is only required in cases where modifications are 
necessary. There are some additional supplements required if post translational modifications 
are anticipated. This is typically due to the fact that the cell loses its ability to perform these 
modifications after the destruction of the membrane and periplasm. The lipids of the cell 
membrane are necessary for the correct folding of membrane proteins while the the 
periplasm supports the formation of disulfide bonds. The challenges can be overcome by 
using the following methods. 
 
For proteins that require disulfide bonds, iodoacetamide (IAM) is used to pretreat 
extract, usually for 30 minutes at room temperature. IAM inactivates the cytoplasmic 
oxidoreductases by deactivating the free sulfhydryl groups. This slightly reduces overall 
protein production, but the sulfhydryl redox potential is stabilized [71,145]. Glutathione 
buffer containing oxidized glutathione (GSSG) and reduced glutathione (GSH) is also 
incorporated to promote the formation of disulfide bonds through the manipulation of the 
redox environment [71,145]. Recently, the researchers at Sutro have shown that GSH is not 
required for the successful expression of aglycosylated antibodies [146]. DsbC is a 
periplasmic disulfide bond isomerase that can be expressed in vivo and stored for later use. 
[147]. It has often been shown to significantly improve oxidative protein folding [145]. Its 
primary role is to rearrange disulfide bonds that have been incorrectly formed. When 
removed from reactions expression disulfide bonded proteins, the amount of active protein 
has been noted to decline by more than 80% [147].  
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Expression of membrane proteins requires additional supplements since their 
structure involves regions of high hydrophobicity that can foul folding. To overcome the lack 
of a cellular membrane, lipids can be introduced as detergents, micelles, nanodiscs, 
liposomes, inverted vesicles, and minimal biological membranes to enhance the production, 
and folding, of membrane proteins [10,11]. This method has been used to successfully 
express mammalian proteins like human glucosylceramide synthase (GlcT), human ᵧ-
secretase subunits, and human claudin-family proteins in vitro using the soluble membrane 
fragment (S-MF) and precipitating membrane fragment (S-MF) methods followed by 
chromatography for purification [148]. 
Glycosylation is not an endogenous process in E. coli, but this challenge is currently 
being addressed to enable glycosylated proteins to be made in E. coli based CFPS. 
Glycosylation machinery such as glycosyltransferase can be added to the CFPS reaction [82] 
and the cell extracts are optimized for glycosylation (e.g. E. coli strain CLM24) [149]. 
Recent work has developed a method of asparagine-linked glycosylation that incorporates 
these methods for site-specific glycosylation [149]. 
Table 2.1 – Supplements added to Cell Free Protein Synthesis (CFPS) reactions spanning 
historic recipes to current methods prevalent in literature today. Representative papers of 
PANOx are [73], for PANOX-SP are [32,45,75], for Cytomim are [6,7,78], for 3-PGA are 
[4,57], and for CP are [40,46,112]. 
 
Nirenberg 
1961 
Zubay 
1973  
Spirin 
1995  
Kim 
1996 PANOx  PANOx-SP  Cytomim 3-PGA CP 
HEPES - - - 
57 
mM 57 mM 0 - 57 mM - 50 mM 
28.5 - 
57 
mM 
Tris 100 mM 44 mM - - - - - - - 
Potassium 
Phosphate - - - - - - 
10 - 15 
mM - - 
ATP 1 mM 2.2 mM - 
1.2 
mM 1.2 mM 1.2 mM - 
1.5 
mM 
1 - 1.2 
mM 
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Table 2.1 (continued) 
GTP 0.03 mM 
0.55 
mM - 
0.85 
mM 
0.85 
mM 0.85 mM - 
1.5 
mM 
0.85 -
1 mM 
CTP 0.03 mM 
0.55 
mM - 
0.85 
mM 
0.85 
mM 0.85 mM - 
0.9 
mM 
0.85 -
1 mM 
UTP 0.03 mM 
0.55 
mM - 
0.85 
mM 
0.85 
mM 0.85 mM - 
0.9 
mM 
0.85 -
1 mM 
AMP - - 1 mM - - - 1.2 mM - - 
GMP - - 
0.5 
mM - - - 0.85 mM - - 
CMP - - - - - - 0.85 mM - - 
UMP - - - - - - 0.85 mM - - 
cAMP - 0.5 mM - 
0.64 
mM - - - 
0.75 
mM 
0 - 
0.65 
mM 
Acetyl Phosphate - - 25 mM - - - - - - 
PEP 5 mM 21 mM - 
52 
mM 33 mM 33 mM - - - 
PEP Kinase 20 ug/mL - - - - - - - - 
3-PGA - - - - - - - 30 mM - 
Creatine 
Phosphate - - - - - - - - 
50 - 
80 
mM 
Creatine Kinase - - - - - - - - 
3.2 - 
200 
ug/mL 
Pyruvate - - - - - - 
0 - 35 
mM - - 
Pyruvate Kinase - - - 
0.3 
U/mL - - - - - 
Folinic Acid - 
27 
ug/mL 
10 
ug/mL 
34 
ug/mL 
34 
ug/mL 
34 - 170 
ug/mL 
0 - 34 
ug/mL 
34.9 
ug/mL 
34 
ug/mL 
E. coli tRNA - 
100 
ug/mL 
340 
ug/mL 
170 
ug/mL 
170.6 
ug/mL 
85 - 171 
ug/mL 
0 - 170.6 
ug/mL 
200 
ug/mL 
0 - 
170 
ug/mL 
T7 RNA 
polymerase* - - - 
33 
ug/mL 
100 
ug/mL 100 ug/mL 
20 - 100 
ug/mL - - 
20 amino acids** 0.05 mM 
0.22 
mM 50 uM 
0.5 
mM 2 mM 2 mM 2 mM 
1 - 3 
mM 2 mM 
NAD - - - - 
0.33 
mM 0.33 mM 
0 - 0.33 
mM 
0.33 
mM - 
CoA - - - - 
0.26 
mM 0.27 mM 
0 - 0.26 
mM 
0.26 
mM - 
FAD - 
27 
ug/mL - - - - - - - 
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Table 2.1 (continued) 
p-Aminobenzoic 
Acid - 
11 
ug/mL - - - - - - - 
Pyridoxine HCL - 
27 
ug/mL - - - - - - - 
Total Parenteral 
Nutrition  
27 
ug/mL - - - - - - - 
Potassium 
Glutamate - - - 
208 
mM 
200 
mM 30 - 175 mM 
130 - 260 
mM 
20 - 
140 
mM 
90 - 
200 
mM 
Potassium Acetate - 55 mM - - - - - - - 
Potassium 
Chloride 50 mM - - - - - - - - 
Ammonium 
Glutamate - - - - - 10 mM 
0 - 10 
mM 
0 - 15 
mM - 
Ammonium 
Acetate - 27 mM - 
36 
mM 80 mM - - - 
0 - 80 
mM 
Magnesium 
Glutamate - - - - - 10 - 16 mM 8 mM 
0 - 6 
mM - 
Magnesium 
Acetate 50 mM 
14.7 
mM - 
16 
mM 16 mM - - - 
11 - 
24 
mM 
Sodium/Potassium 
Oxalate - - - - 2.7 mM 2.7 - 4 mM 4 mM - - 
Calcium Acetate - 7.4 mM - - - - - - - 
Putrescine - - - - - 1 mM 0 - 1 mM - - 
Spermidine - - - - - 1.5 mM 1.5 mM 1 mM - 
PEG - 
1.6% 
w/v - 
4% 
w/v 2% w/v - - 2% w/v 
0 - 2% 
w/v 
DTT - 
1.37 
mM - 
1.7 
mM - - - 
0 - 1 
mM 
0 - 2 
mM 
Mercaptoethanol 6 mM - - - - - - - - 
IPTG - - - - - - - 
0 - 1 
mM - 
* T7RNAP can be produced via IPTG induction when using the DE3 strain 
** Concentration is for each individual amino acid 
2.2.6 Additive Preparation and Storage Methods 
The CFPS workflow can be streamlined by combining all supplements in a single 
premix, or master mix. These master mixes can be stored at -80°C and maintain their activity 
after 3-4 freeze thaw cycles. In 2012, the Swartz group published methods for creating a 
43 
PANOx-SP premix [43]. In 2012, the Noireaux group published step-by-step methods for 
creating a 3-PGA system, here [35]. In 2015, Sutro Biopharma shared their minimalist, 
optimized Cytomim recipe [7]. The Noireaux lab has also published a method for making a 
soluble amino acid mix [151]. It is highly recommended to follow these guidelines since not 
all the components are easily soluble in water and consolidating the supplements in a single 
master mix can speed up the preparation of CFPS reactions, as well as significantly reduce 
batch-to-batch variation. 
2.3 Conclusions 
There are many options and inherent flexibility when choosing supplements for CFPS 
to express proteins, yet they do have a direct impact on the expression efficiency. The 
decision should be based on the rate, cost, and complexity of the target protein. For example, 
a system that uses phosphorylated glycolytic intermediates might be the best choice for 
small-scale research purposes since they produce high concentrations of protein quite rapidly. 
However, these energy systems tend to have a higher supplement cost per mass of expressed 
protein and would not be a good candidate for large volume scale-up. In contrast, the 
Cytomim system is a good option for those who are more interested in cost efficiency. The 
large number of recipes and flexibility of CFPS bespeaks much room for supplement 
optimization and further simplification of additive recipes. In practice, after a primary energy 
substrate is selected, the remaining supplements should be optimized empirically for the 
individual expression needs of a particular protein. 
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CHAPTER 3.    PROCESS OPTIMIZATION FOR SCALABLE E. COLI EXTRACT 
PREPARATION FOR CELL-FREE PROTEIN SYNTHESIS 
Modified from a manuscript published in Biochemical Engineering Journal 
By Jared L. Dopp1 and Nigel F. Reuel1 
1Iowa State University Department of Chemical and Biological Engineering 
Jared Dopp conducted all experimentation, wrote all text except the section on 
designed experiments, and analyzed all data except the response surface plot in Matlab. 
Dr. Nigel Reuel edited the drafts, wrote the section on designed experiments, and was 
responsible for the response surface Matlab code. 
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Abstract 
Cell-free protein synthesis (CFPS) is a versatile tool for protein research and 
biomanufacturing. In this work, large volume cell extract preparation methods from 
Escherichia coli were optimized with a unit operations approach. Using face centered cubic 
designed experiments, optimized time points for IPTG induction (to produce T7 polymerase) 
and cell harvest were determined. These were at times corresponding to 28 and 58.5% the 
overall growth extent as measured by absorption; for 1 L cultures in 2.5 L shake flasks in our 
incubator, this amounted to 201 min and 255 min respectively. The cell pellet was washed in 
S30 buffer once for 10 mins and stored at -80°C without flash freezing in nitrogen. Cell lysis 
was simplified by diluting the cells to one part S30 buffer, one part DI water, and one part 
cells by mass and then passing through a continuous French press for one cycle at 25,000 psi. 
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The resulting suspension is clarified with one low speed centrifugation step at 12,000 xg for 
10 mins (4°C). All extract is then immediately frozen in a pilot-scale lyophilizer (-70°C) and 
dried under optimal conditions determined as 4 hrs under vacuum (200 mTorr) while holding 
a shelf temperature of 15°C. The lyophilized extract showed no statistically significant 
difference in sfGFP expression levels when compared to an optimized, lower-volume 
sonication protocol and improved performance over extract from commercial kits. As an 
increasing number of efforts in CFPS expand beyond the bench top, scalability and reliability 
become increasingly important if it is to become a viable tool for biomanufacturing. 
3.1 Introduction 
Cell-free protein synthesis has become a reliable a tool for biomedical and 
biotechnology discovery, as well as material prototyping [1–3]. Cell-free systems have been 
applied to sensors [4] and demonstrated against a wide array of analytes such as endocrine 
disruptors [5], viral RNA [6,7], and quorum sensing molecules [8,9]. Sensors constructed 
with CFPS produced capture proteins have been used to detect single protein binding events 
down to the pM level [10]. This in vitro method employs three components to express 
proteins: 1) genetic template(s) (plasmids or PCR products) to specify the translated protein, 
2) additives to support transcription and translation (rNTPs, amino acids, energy substrates, 
etc.) and 3) cell extract (Fig 3.1a). The cell extract is the cytoplasmic content harvested from 
living cells that contains necessary machinery (ribosomes, glycolytic enzymes, and 
membrane lipids) to produce the desired proteins. Varying levels of cell extract (24-30% by 
volume) can be used in CFPS reaction, depending on additive composition and desired rate 
of expression [8]. Cell extracts are typically used fresh or are flash frozen in liquid nitrogen 
and are stored at -80°C to preserve the vitality of the cell machinery [11]. Prolonged 
exposure to warmer temperatures of 4°C and 25°C has shown a decline in extract 
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productivity [12]. Steps in eliminating the cold chain have been pursued, such as using 
lyophilization to dry out the extract with little effect on the extract productivity [12,13]. 
Process optimization for small volumes (≤1.5 mL) of E. coli extract production have also 
been pursued for the purposes of increasing protein synthesis efficiency and reproducibility 
[14]. In order to make this a more robust expression tool for larger scale protein production, 
herein we focus on cell extract preparation and lyophilization optimization for larger batches 
(>100 mL) using pilot scale tools. 
 
Figure 3.1 – a) Three main components of a cell free protein synthesis reaction: additives, 
DNA template, and cell extract. b) Cell free extract preparation can be simplified to five unit 
operations: cell growth, pellet and washing of cells, lysis of cells, clarifying the extract 
supernatant, and lyophilizing. 
Traditional cell extract preparation can easily become the most time consuming part 
of setting up a cell-free reaction. Historically, the process steps included cell harvest, 
centrifugation, multiple washing steps, membrane disruption, multiple extract clarifications, 
a run-off reaction, and dialysis. Since then, there have been multiple recent studies aimed to 
simplify these steps. Early attempts targeted the washing, centrifugation, and dialysis steps 
and were simplified to reduce extract preparation time from ~10.5 hrs to ~6 hrs [15]. Soon 
thereafter, extract clarification was simplified by the introduction of a single low-speed 
centrifugation step for 10 mins with no dialysis steps, as shown before in the literature [16]. 
In another attempt at optimization, centrifugation, run-off reactions, and dialysis steps were 
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simplified further and this was sufficient to create enough extract for one of the largest 
published cell-free reactions, with a final volume of 100 L [17]. Another study on 
streamlining extract preparation evaluated the efficacy of different membrane disruption 
methods (high-pressure homogenization, sonication, bead vortexing, lysozyme treatment, 
freeze-thaw cycling) while reducing the time required in some centrifugation steps [11]. A 
more recent study drastically simplifies extract prep by combining many of the 
aforementioned improvements with minimal impact on lysate performance [14]. This 
provided a reliable method to produce high quality extract but was limited to cell disruption 
by tip sonication with small working volumes (≤1.5 mL). At a sonication time of roughly 5 
min per 1 mL sample using a pulse to keep temperature low, it would be inconvenient to 
process larger cell growths. Another possible route to large volume extract preparation is 
using a bacterial strain that is programmed for autolysis; this has been demonstrated with 
BL21-Gold (DE3) cells using a pAD-LyseR plasmid [8]. This plasmid encodes for lambda 
phage endolysin that can lyse the cell membrane after it is weakened by a single freeze-thaw 
cycle. This drastically reduces the time necessary for cell lysis, can potentially be used for 
larger volumes, and eliminate the need for capital equipment such as a French press or tip 
sonicator. However, limitations of the technique are long incubation times (~1.5 hr) at room 
temperature and extended centrifugation steps to clarify the extract.  
Lyophilization (freeze-drying) has also been applied to small scale extract 
preparations as a means to improve shelf stability and reduce storage requirements. A typical 
bench-top lyophilization process involves flash freezing a small sample (1-10 mL) with 
liquid nitrogen, covering the sample with a breathable material (e.g. Kimwipe), and placing it 
under pressure in a lyophilizer at room temperature. By sublimating the water, the storage 
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volume is reduced and the extract has increased resistance to degradation. The first published 
examples of lyophilization for cell free extracts were shown in 2014 [12]. The study 
compared the productivity of lyophilized versus aqueous extract stored at varying 
temperatures (-80, -20, 4, and 25°C) over a period of 90 days. The findings showed that 
lyophilized and aqueous extracts performed equally well when stored at -80°C and -20°C. 
They also showed that the lyophilized extract retained its ability to express protein at 
elevated temperatures (4°C and 25°C) albeit at an 80% reduction at 25°C after 90 days 
compared to storage at lower temperature. The same research group has subsequently 
demonstrated production of an active onconase [18] and endocrine disruptor sensor [5] from 
lyophilized extract. The lyophilized extract was able to maintain activity for a year in all 
cases except when stored at 25°C [12]. Subsequent studies from another group demonstrated 
lyophilized CFPS reactions on paper discs for sensors [6]. The paper discs housed a synthetic 
gene circuit governed by a toehold switch that was activated by a complementary mRNA 
sequence. The method was very effective at detecting the Ebola virus, but again was 
accomplished with small batches of extract [6]. The utility of lyophilized extract has been 
further demonstrated by producing therapeutic proteins such as antimicrobial peptides, 
vaccine antigens, and antibody conjugates. [19]. 
In this work we build upon these small-scale extract preparation and lyophilization 
studies by developing and optimizing methods for producing large volumes of cell extract. 
We present a unit operations based approach for increasing workflow efficiency and reliable 
scale-up of the extract preparation process (Fig 3.1b). The concept of unit operations is a 
method of simplifying a complex process into a series of discrete unit components, called 
operations. This method was developed by chemical engineers in the early 1900s to design 
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increasingly complex chemical plants, which were broken into manageable units for analysis 
(input streams, reactors, separations, etc.) [20]. Likewise, we use this concept here by 
isolating and optimizing each step individually to improve the overall extract preparation 
process by reducing the time and manual steps, while maintaining extract efficiency. These 
unit operations include fermentation (cell growth), centrifugation (washing), membrane 
disruption (cell lysis), centrifugation (clarifying extract), and lyophilization. The objective of 
this work is to make CFPS more cost-effective by reducing the amount of person-hrs 
required to produce large batches of robust, reliable, productive, and shelf-stable extract with 
good batch to batch consistency. 
3.2 Materials and Methods 
3.2.1 Cell Growth in Shaker Flasks 
Starter cultures of E. coli BL21 Star™ (DE3) cells were grown overnight in 
Lysogeny broth (LB) media at 37°C and 230 RPM in 3 or 20 mL cultures using a MaxQ 
4000 shaker (Thermo Scientific). Tunair shake flasks (500 mL and 2.5 L) were used to 
culture 150 mL and 1 L volumes of 2x YTPG [21] inoculated with 3 mL or 20 mL starter 
culture respectively. Culture times ranged from 3 to 5 hrs, depending on the experiment. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added at 1 mM final concentration to 
induce T7 polymerase expression. Exposure time to the inducer ranged from 35 to 85 mins 
based on experiment. Cells were pelleted by centrifugation at 5,710 xg and 4°C for 15 mins. 
Cell pellets were then transferred to a 50 mL conical tube and washed (resuspended) in 30 
mL of S30 buffer (1 M tris-acetate, 1.4 M magnesium acetate, 6 M potassium acetate, and 
2M DTT). The cell suspensions were then centrifuged at 7,000 xg and 4°C for 10 mins. The 
cells were flash frozen in liquid nitrogen and then stored in -80°C freezer or immediately 
lysed. 
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3.2.2 Sonication Cell Lysis 
Cells were resuspended in 1 mL S30 per 1 g wet cell mass and lysed via tip 
sonication using a Qsonica Q125 with a 2 mm (5/64 inch) tip at 50% amplitude. The 
sonication was performed at -5°C in a jacketed cooling vessel using an optimized pulse 
duration of 10 s on 10 s off and an optimized energy input 532 J that were determined in a 
recent study [14]. The suspension was then centrifuged at 12,000 xg and 4°C for 10 mins. 
The clarified lysate was then collected and flash frozen in liquid nitrogen and stored at -80°C. 
The total cell mass collected for lyophilization experiments was 17.70 g. 
3.2.3 Continuous Flow French Press Lysis 
The frozen cell pellet was resuspended as before with 1 mL of S30 buffer per gram of 
wet cell mass with the addition of 0 to 2 mL of DI water depending on the experiment. A 
continuous flow French press homogenizer (Avestin EmulsiFlex C3) was then used to lyse 
the cells at a pressure swing of 25,000 - 30,000 psi. The resulting suspension was then 
centrifuged at 12,000 xg and 4°C for 10 mins. The supernatant was collected in a single 
conical tube for measuring and homogenization. The process yielded roughly 40 mL of dilute 
extract which was stored in aluminum weighing dishes (Fisher Scientific) in 3 mL aliquots 
for the lyophilization study. 
3.2.4 Lyophilization 
All lyophilization was carried out in a 35 L VirTis Genesis Pilot-scale Lyophilizer 
(SP Scientific) with start sample volumes of 3 mL. The samples were frozen in the 
lyophilizer at a temperature of -70 °C. An initial hold time of 30 mins was sufficient to fully 
freeze the extract. The pilot scale lyophilizer has the ability to control shelf temperature, thus 
temperatures of 15, 25, 50, and 75°C were used as sublimation hold temperatures in this 
work. Total lyophilization times of 1, 2, 4, 12, 24, and 48 hrs were studied. Each extract 
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sample was weighed prior to lyophilization and covered with a Kimwipe to prevent sample 
loss during handling and pressurization. All lyophilization was carried out at 200 mTorr. The 
resulting mass of lyophilized extract was 1.82 g which equates to 29.04 mL of concentrated 
extract upon the addition of DI water. 
3.2.5 Cell-Free Reaction 
The expression genetic template used in this work was the pJL1-sfGFP plasmid (gift 
from the Jewett lab) that encodes for sfGFP, a protein that can be readily assayed using its 
inherent fluorescence. Reactions were carried out in 15 µL volumes using a black-walled, flat 
bottom 384 well plate (Greiner Bio-One). All reactions were done in multiples of five to 
mitigate any effects of variation between wells. Reactions were conducted at 37°C and 
orbitally shaken for 4 hrs. The type of additives used in these reactions was a modified 
cytomim system based on that used by Sutro Biopharma [22] with final concentrations of: 
30% v/v S30 E. coli extract, 10 ng/µL plasmid DNA, 260 mM potassium glutamate, 8 mM 
magnesium glutamate, 4 mM potassium oxalate, 1.5 mM spermidine, 15 mM potassium 
phosphate (pH 7.0), 1.2 mM AMP, 0.86 mM each of GMP, UMP, and CMP, and 2 mM 19 
amino acids with 1 mM tyrosine. T7 RNA polymerase was not added since it was 
overexpressed via IPTG induction during cell growth. Oxidized glutathione (GSSG) was also 
omitted since no disulfide bonded proteins were expressed in this work. All lyophilized 
extract was reconstituted according to the equation volume H2O (mL) = (mass of lyophilized 
extract (g))(1.5 mL/0.094 g). Where the factor 1.5 mL/0.094 g was obtained by measuring 
the mass of 1.5 mL of extract, prepared via sonication, after lyophilization (15°C for 12 hrs). 
3.2.6 Quantification of Cell Density and sfGFP Fluorescence 
All absorbance and fluorescence measurements were taken with a Synergy Neo2 HTS 
Multi-Mode Microplate Reader (BioTek). Cell density was measured by transferring 200 µL 
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of sample from the shake flask to a well plate and recording the absorbance at 600 nm. 
Fluorescence of sfGFP was measured at excitation of 485 nm and emission of 528 nm using 
a ±20 bandpass window and 61 gain. 
3.3 Results and Discussion 
3.3.1 Cell Growth Optimization 
The first unit operation for CFPS extract preparation is cell culture to produce healthy 
cells for the extract. Maximizing overall cell mass is not the best driving parameter to 
produce a productive extract. In fact, higher cell mass obtained by slower growth rates 
decrease the concentration of translational machinery such as ribosomes [23]. It has been 
shown that this has a deleterious effect on cell-free expression efficiency. Faster growth rates 
lead to a higher concentration of ribosomes, and thus a more productive cell extract [24]. 
Thus one factor to optimize is the growth time of the cells. 
In our approach, the cost and complexity of additives needed for CFPS reactions is 
simplified by expressing T7 RNA polymerase during cell growth. This protein transcribes the 
DNA template into mRNA which translates the protein sequence at the ribosome. BL21 
Star™ (DE3) cells contain the DE3 lysogen that carries the gene for T7 polymerase under 
control of the lacUV5 promoter [25]. It can be induced by addition of Isopropyl β-D-1-
thiogalactopyranoside (IPTG). The optimal duration of IPTG induction introduces another 
variable for optimal extract performance. 
Because culture and IPTG exposure times were likely coupled, a face centered cubic 
(FCC) design of experiment was used to study the multivariate effect and find the optimal 
point for these two parameters. FCC is a type of central composite design (CCD) approach to 
efficiently plan a small subset of experiments to cover the experimental space and model the 
response surface with statistical significance.  FCC is preferred to other CCD designs, as it 
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keeps our experimental conditions at the upper and lower bounds set (e.g. no internal or axial 
points).  Designed experiments, such as the one used in this work, are powerful tools because 
they can reduce the number of experiments required, thereby reducing cost and time invested 
[26]. In brief, an FCC design was generated for culture times spanning 3 to 5 hrs and IPTG 
exposure times of 35 to 85 mins, resulting in nine unique runs and four center replicates 
which were all blocked in triplicates (39 total runs - see Supplement 1 for additional detail). 
This designed experiment was conducted with 150 mL cultures in 500 mL shake flasks. The 
experimental points were fit with a quadratic response surface model (Fig 3.2a) and was used 
to identify optimal times for cell harvest and IPTG exposure which were 4.6 hr and 60 min 
respectively. The response surface contours also suggest that extract activity is more 
sensitive to overall growth time than it is to IPTG induction time.  
As the goal for this study was large scale production of extract, the next step was to 
scale up the growth of cells in 2.5 L baffled flasks with 1 L culture volumes. Absorbance at 
600 nm (OD600) is the most frequently used measure to report ‘absolute’ growth conditions 
for cells. This is misleading, as absorbance measures are highly dependent on the apparatus 
used to make the measurement (path length, microwell plate or cuvette geometry, excitation 
bulb strength, etc.) and components of the media [27]. As such, these measurements can vary 
widely between research groups. A more absolute measure would be recording the actual cell 
density (# cells/ml), however this process requires a flow cytometer or much patience 
counting plated colonies on agar. In the near future, in situ turbidity sensors could be used to 
provide more robust measurements, however its utility is still to be determined [28].  
In this work we translate the convenient OD600 measurements into a more ‘absolute’ 
measure of cell growth points by first observing the full growth profile of the cells in the 
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shake flask. This results in a sigmoidal growth profile that is fit well with a four parameter 
logistics curve (Supplement 2). The model fit determines the OD600 span that the cells are 
able to obtain in that growth volume. The optimal points found for one culture volume is then 
expressed as percentages of this growth span, which then allows for translation to another 
volume. This was done for our 150 mL culture (Fig 3.2b) where we determined the optimal 
induction and growth times were 216 and 276 min respectively from the designed 
experiment. These times were found to correspond with 28 and 58.5% of the OD growth 
span respectively. Then the growth curve was obtained for 1 L cultures (Fig 3.2c) and the 
optimal growth span percentages were used to determine the optimal induction and harvest 
times of 201 and 255 mins respectively. These optimal growth conditions were then set for 
this unit operation and we then focused on the next step, cell pelleting and lysis of the cells. 
 
Figure 3.2 – Optimization of cell growth conditions. a) Effect of total culture time and IPTG 
exposure time on CFPS productivity from 150 mL cell cultures as measured by sfGFP 
production (z axis = RFU). Quadratic response surface generated from 78 tests, yielding 
optimal point (●) at 4.6 hr culture time and 1 hr IPTG exposure. b) Growth curve from 150 
mL culture showing four parameter logistic curve fit (red solid) and the optimal induction 
and harvest time points found from the response surface. c) Optimal induction and harvest 
time points determined for a scaled up, 1 L cell culture using the four parameter logistic 
curve fit. 
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3.3.2 Cell Pelleting and Wash 
The first centrifugation step isolates the cells from the growth media and metabolic 
waste. We found this could be done conveniently using a large volume, floor model 
centrifuge. The cell pellets are then collected and transferred to 50 mL conical tubes with 
cold S30 buffer. The cells are then resuspended (washed) and centrifuged once again for 10 
mins. This removes any remaining media and metabolic waste that can interfere with the 
CFPS reaction. Previously it was common to repeat this step two more times (total of three 
washes) but an extensive study showed no significant difference in cell-free expression by 
reducing to only one wash [15]. Therefore, we implemented a single wash to reduce 
centrifugation time, vortex time, and S30 usage and found no difference in our extract 
performance to previously optimized extract [14]. At this point the wet cell mass was 
measured and the cells were stored or directly lysed. Current studies recommend flash 
freezing the extract and storing at -80°C to improve the lysing process by disrupting the inner 
membrane of the cell through one freeze-thaw cycle [8]. However, in this work we 
determined that freezing at -80°C without flash freezing was equally effective. 
3.3.3 Lysing Protocols 
Prior to lysing, the frozen cells were thawed and resuspended in S30 buffer. The 
amount of buffer added is typically 1 mL of S30 per 1 g of wet cell mass [14]. We noticed 
that this ratio worked well for small volume lysis by sonication but is too viscous for a 
continuous homogenizer. The continuous flow homogenizer used for this work performed 
inconsistently with the viscous, 1:1 mass ratio. It would frequently clog or have irregular 
pressure swings. Because we knew the downstream lyophilization unit operation could 
remove excess water, we proposed adding extra water to dilute the sample and improve the 
homogenizer operation. When diluting we maintained 1 mL of S30 buffer to 1 gram of wet 
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cell mass and then added DI water for any additional dilution volume. This was done to keep 
the final concentration of S30 buffer salts equal to that of the sonication protocols after 
driving off the extra water via lyophilization. This was done to allow for better comparison to 
sonicated extract controls and it has been shown that the ratio of S30 buffer to wet cell mass 
impacts extract performance with the best activity occurring at ratios of 1:1 and 1:1.27 (mL 
S30 buffer to g wet cell mass) [14]. The continuous flow homogenizer (Fig 3.3a) also 
allowed for multiple passes to increase lysis efficiency and we included this variable to see 
its effect on extract performance. 
A two variable face centered cubic (FCC) designed experiment was used to explore 
the effect of dilution volume and number of passes on extract performance (Supplement 3). 
The experimental ranges were set at 1 to 3 mL total dilution volume (0 to 2 mL of additional 
DI water added to the 1 mL of S30 buffer per gram cell mass) and 1 to 5 passes. However, 
the viscous 1:1 (buffer to wet cell mass) dilution experiments did not consistently pass 
through the homogenizer. A quadratic model response surface was fit to the remaining higher 
dilution points and it was apparent that diluting more than 2 ml per gram wet cell mass was 
not beneficial (Fig 3.3b). We then fixed our dilution to a 2:1 mass ratio (1 mL buffer + 1 mL 
DI water per gram of wet cell mass) to do a more detailed study on the effect of number of 
passes through the homogenizer. All samples were lyophilized (12 hr) and resuspended in DI 
water according to the ratio of water removed from lyophilized sonicated samples (see 
methods).  The reconstituted extracts were then tested for productivity using the sfGFP 
plasmid (Fig 3.3c). We observed lower extract activity with each pass through the French 
press. This is most likely due to denaturation from shearing of the endogenous proteins 
(ribosomes and enzymes) required for transcription and translation. There could also be a 
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denaturing effect from increased heat as a result of multiple exposures to high pressure. We 
also observed no significant difference of activity between the single pass extract and the 
standard sonication protocol [14] that we used as a control. All subsequent experiments were 
conducted with lysate that had been exposed to a single pass. 
 
Figure 3.3 – Optimization of cell lysis with continuous flow French press. a) Diagram of 
continuous flow French press in which cell suspension is poured in hopper, lysed by piston at 
swing pressure (Pg), and then cooled by ice bath and collected. b) Determining effect of 
dilution volume added per gram dry cell mass and number of passes through homogenizer 
with a partial, quadratic response surface model as measured by resultant extract sfGFP 
expression ability (z axis = RFU). c) Studying effect of number of passes through French 
press at constant dilution ratio of 2 mL per gram dry cell mass as reported by sfGFP 
production. 68.3% confidence interval for n = 5 shown as shaded, color regions. 
 
3.3.4 Extract Clarification 
The final centrifugation step is used to remove cell debris from the lysate. This 
process is typically referred to as clarification and was traditionally conducted twice at high 
speeds (30,000 xg) and low temperatures (4°C) for 30 mins [15]. However, a recent study 
has shown that cell extract performance is not significantly impacted if centrifuged once at 
lower speeds (12,000 xg) for 10 mins [14]. This simplified protocol was followed for this 
work with no negative effect on the protein expression efficiency from larger volumes of 
extract. 
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3.3.5 Lyophilization Optimization 
Lyophilization is used to stabilize and store proteins at a reduced volume and high 
temperatures by removing water. In this process, extract is frozen, subjected to vacuum (200 
mTorr) while running a condenser that collects the sublimated vapor from the extract liquid. 
Small-scale lyophilizers have been used in the past for freeze-drying cell extract [6,8,12]. 
However, small-scale lyophilizers are constrained to small sample volumes, operating at 
ambient temperature, and longer dry times. The purpose of this study was to determine the 
utility of a pilot-scale lyophilizer to improve extract dry time and performance. This unit has 
the ability to initially freeze samples at -70°C, thus obviating the need for freezing samples 
after cell lysis. It also has shelf temperature control to tune sublimation conditions during the 
drying process and a large sample working volume (>1 L distributed on 5 shelves). In this 
manner, large volumes of extract can be processed 
First the effect of lyophilizing extract at varying shelf temperatures was studied (Fig 
3.4a). Again, we can see no significant difference in extract activity between lyophilization at 
15°C and the standard sonication protocol. However, higher lyophilization temperatures 
result in significantly lower sfGFP expression. We then determined the extent of water loss 
as function of time when lyophilizing at 15°C by observing the percentage mass loss (Fig 
3.4b). After one hr of lyophilization, only 48.5% of the total mass was lost. However, 
increasing the time to two hrs drastically improved mass loss with a total of 91.5% total mass 
being driven off as water. Water loss improvements were very small after this point with 4, 
12, 24, and 48 hrs losing a total mass of 94.8%, 95.2%, 95.1%, and 96.2% respectively. The 
consistency of the lyophilized extract was visibly drier as the lyophilization time increased 
above 2 hrs (Supplement 4). The productivity of these extracts (4, 12, 24, and 48 hrs) was 
then tested to find the best lyophilization time (Fig 3.4c). All samples performed similar to 
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the sonicated standard with the 12 hr sample having a slightly better average trend than the 
others. 
This data shows that lyophilization conducted at lower temperatures preserves extract 
activity much more effectively than at higher temperatures. Although increasing the shelf 
temperature during lyophilization would drive off water faster, it causes an obvious decrease 
in extract activity when lyophilized for the same amount of time as a sample using lower 
shelf temperature. It appears that although the extract is dry, it is still highly susceptible to 
degradation at these increased temperatures. We found it to be unnecessary to speed up the 
process since 94.8% of mass loss occurs in the first four hrs at 15°C and extract lyophilized 
for 4 hrs performs as well as the sonication standard. 
 
Figure 3.4 – Optimization of extract lyophilization with pilot scale lyophilizer. a) Effect of 
shelf temperature on extract productivity after 12 hr lyophilization as measured by sfGFP 
production, color regions. b) Mass reduction of extract as function of time in lyophilizer at 
shelf temperature of 15°C. c) Effect of lyophilization time on cell free extract productivity as 
measured by sfGFP production. 68.3% confidence interval for n = 5 shown as shaded regions 
in (a) and (b). 
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3.3.6 Comparisons to Other Products and Protocols 
To further determine the quality of the extract produced in this work, we compared its 
expression levels to other extracts presented in literature and available commercially.  By 
using an sfGFP RFU to mass concentration calibration curve (Supplement 5) the lyophilized 
extract (Fig 3.4a) product concentrations at 12 hr were estimated as 97 µg/mL for sonicated, 
102 µg/mL for lyophilized at 15°C, 60 µg/mL for lyophilized at 25°C, 47 µg/mL for 
lyophilized at 15°C, and 19 µg/mL for lyophilized at 75°C. When compared to recent work 
by Sutro Biopharma [22], we see that they were able to express roughly 1500 µg/mL of 
TurboGFP. However, Sutro’s reactions are conducted under conditions different from this 
study (temperature of 30°C, time of 14 hrs, shaking at 600 rpm, volume of 100 µL, and a 
breathable sealing film). Sutro also used the 14C labeled leucine to determine the final 
protein yield [22]. Another useful comparison is to the work of Kwon and Jewett from which 
we derive our sonication protocol [14]. After optimizing their process, sonicated CFPS 
produced roughly 500 µg/mL of the same sfGFP (identical plasmid). However, again the 
reaction conditions differ (4 hrs at 37°C using a PANOx-SP energy system) [29] and the 
method of quantification is different (14C labeled leucine to determine the final protein 
yield).  Because comparison to previous literature findings is never completely direct, we 
also performed a comparison of extract from this work to other commercial kits, expressed 
on the same plate, using the same plasmid, extract quantities, and additives.  The CFPS kits 
evaluated were the Promega S30 T7 High-Yield Expression kit and the NEB PURExpress® 
kit, and for both the extract produced from this manuscript’s method exhibits noticeably 
higher expression of sfGFP over a four hr time period when using the same additive mix 
provided by the vendor (Fig 3.4a). The quantitative results are as follows: Promega extract 
with Promega additives 212 µg/mL, lyophilized extract with Promega additives 308 µg/mL, 
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NEB extract with NEB additives 84 µg/mL, and lyophilized extract with NEB additives 147 
µg/mL (as determined from the sfGFP RFU to concentration calibration curve presented in 
Supplement 5). 
 
Figure 3.5 – Benchmark tests for the method of extract preparation used in this work. a) 
Lyophilized extract tested against equal volumes of extract from the Promega S30 T7 High-
Yield Expression System and the NEB PURExpress® kit using their respective additives 
where (E) refers to extract and (A) refers to additives. b) A comparison of the total time 
required to go from the wet cell pellet to a usable extract when using the sonication protocol 
and the French press + lyophilization protocol. 
 
By comparing the time of each unit operation step presented in this method to that of 
the sonication method, one can also obtain the amount of wet cell mass where it would be 
more efficient to use this higher volume method. We have observed the times for the 
sonication method as roughly 10 mins per gram of cell mass (a sonication volume of 1 mL 
cell suspension contains 0.5 g of cells). It takes approximately 5 mins to sonicate each 1ml 
sample and an additional 10 mins for clarification once 24 samples are loaded into the 
centrifuge. We estimate the times for the high-volume method as 1 min per 3 grams of cell 
mass; the French press has a flow rate of 10 mL/min where 10 mL of double dilute cell 
suspension contains 3.3 g of cells. The extract is then clarified for 10 mins once 16 samples, 
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of 5 mL each, are loaded into the centrifuge. Finally, for the high throughput method, there is 
a constant time requirement of 4 hr in the lyophilizer and it takes 7 mins to reconstitute one 
gram equivalent of starting wet cell mass. The minimum cell mass needed for the continuous 
French press is roughly 10 g to reach a 30 mL minimum volume. By plotting these time 
requirements as a function of wet cell mass (Fig 3.5b), we see that at 25 g it is more time 
effective to use this process over the optimized tip sonication approach. 
3.4 Conclusions 
In summary, we have developed methods to produce large volumes of shelf-stable, 
CFPS extract with minimal time and processing steps. The resulting extract has demonstrated 
productivity at the same level of recently optimized small-volume extract that uses a finely-
controlled, but unscalable tip sonication method. Optimal induction points for T7 polymerase 
expression and overall culture duration for the cells were found to be at 28 and 58.5% of the 
cell growth extent respectively. Using a four parameter logistics curve fit on the sigmoidal 
growth curve, these optimal points can be translated to times of addition and harvest for any 
shake flask size. Using a continuous flow, French press, it was determined that a 2 mL total 
liquid (1 mL buffer + 1 mL DI water) to 1 gram cell mass dilution worked best to pass 
through the press and that one pass yielded the most active extract. The sublimation 
temperature of the lyophilizer was found to have a great effect on the extract quality with 
15°C found as optimum. Furthermore, pretreatment at -80°C was not needed and a time of 4 
hr was sufficient to drive off 94.8% mass by way of liquid. In this manner large volumes of 
extract (100 mL to 10L) for CFPS reactions can be readily processed with minimal, manual 
intervention. This may prove useful for CFPS-based biomanufacturing, such as cytotoxic 
protein therapies, or development work that requires larger volumes of expressed proteins 
such as biomaterial design. In a single workday, it is possible to grow and harvest cells (5-6 
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hrs), lyse via French press (~30 mins), clarify extract (10 mins), and lyophilize the resulting 
extract (4 hrs) as long as growth media and starter culture have been prepared ahead of time. 
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Appendix 
Response Surface Designed Experiment for Cell Growth 
Response surface design 
A face centered cubic (FCC) response surface design was generated for the two 
variable study with IPTG exposure time varying from 35 to 85 minutes and culture time 
varying from 3 to 5 hours (Fig S3.1). Five replicate points were used at the center point and 
the run order was randomized (total points = 13). Due to inherent variability of low-volume 
CFPS reactions, the experiments were run in triplicate (n = 39). 
 
Figure S3.1 – The experimental points used to generate the response surface. 
After the first run of 39 tests with 3 controls (no DNA) a large amount of variance was 
observed. We ran the experiments again with similar levels of variance (Table S3.1). Rather 
than attempting to decide which values were ‘errors’ from pipetting mistakes or obfuscating 
this variance by fitting only the averages (n = 6) of all the experiments, we decided to fit our 
response surface to all 78 data points. 
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Table S3.1 – sfGFP RFU results from the response surface designed experiment
 
                 
The Matlab code used to fit the 78 data points to a quadratic model is copied in the 
next section. With no reduction in terms, the goodness of fit is as follows: 
Linear regression model: 
    y ~ 1 + x1*x2 + x1^2 + x2^2 
 
 
80 
Estimated Coefficients: 
                    Estimate                SE          tStat         pValue   
                   ___________    ______    _______    __________ 
 
    (Intercept)    -1.6037e+05     37744    -4.2488    6.3384e-05 
    x1                  518.36              529.7    0.97859       0.33106 
    x2                   74618             18638     4.0035    0.00014996 
    x1:x2               18.892          74.885    0.25228       0.80155 
    x1^2               -4.9806          3.6048    -1.3817       0.17135 
    x2^2               -8209.1             2253    -3.6436    0.00050386 
Number of observations: 78, Error degrees of freedom: 72 
Root Mean Squared Error: 9.17e+03 
R-squared: 0.477,  Adjusted R-Squared 0.441 
F-statistic vs. constant model: 13.2, p-value = 4.19e-09 
We note that the overall model R-squared is low (~0.5) so we attempt to improve this 
by removing the cross-term (Exposure Time*Culture Time) that has the highest p-value. This 
results in the following model goodness of fit: 
Linear regression model: 
    y ~ 1 + x1 + x2 + x1^2 + x2^2 
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Estimated Coefficients: 
                    Estimate              SE         tStat           pValue   
                   __________    ______    _______    __________ 
 
    (Intercept)    -1.649e+05     32977    -5.0005    3.8069e-06 
    x1                 593.93            434.06     1.3683       0.17542 
    x2                  75752             17972     4.2149    7.0612e-05 
    x1^2              -4.9806           3.5816    -1.3906       0.16857 
    x2^2              -8209.1           2238.5    -3.6672    0.00046263 
Number of observations: 78, Error degrees of freedom: 73 
Root Mean Squared Error: 9.11e+03 
R-squared: 0.477, Adjusted R-Squared 0.448 
F-statistic vs. constant model: 16.6, p-value = 9.77e-10 
However, this simplified model still has a low R-squared which we attribute to the 
variance of the CFPS reactions from these initial experiments. Systematically dropping 
obvious outliers (such as run 28 and 31 from Experiment 1) does improve the fit 
significantly, but for good data representation we present the model with all data points as 
obtained and rely on the very large sample size for increased confidence in the model 
findings. 
Matlab code for surface design 
This code is used to fit the data in Table S3.1 with a full quadratic model as well as a 
quadratic model with cross term removed. 
function DOEplot 
% Coded by NFR on 2.15.2017 
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%  
% Read in the Data (first two columns are the set points, last column is the output 
D = xlsread('DOEdata_all.xlsx'); 
%  Fit with quadratic model (c1 = IPTG exposure time(T), c2 = overall culture 
time(t))                                 
mdl = fitlm(D(:,1:2),D(:,3),'quadratic') ;  
% Remove the cross term 
terms = 'x1:x2'; % terms to remove 
mdl = removeTerms(mdl, terms); 
% All significant EXCEPT the cross term X1:X2 and X1^2 
P = mdl.Coefficients.Estimate; 
%F1 = @(T,t) (P(1) + P(2)*T + P(3)*t + P(4)*T.*t + P(5)*T.^2 + P(6)*t.^2);  
% <-- NOTE: the wrong plot is given if the '.' notation is not used in the square terms 
F1 = @(T,t) (P(1) + P(2)*T + P(3)*t + P(4)*T.^2 + P(5)*t.^2); 
% Make a contour plot 
Tvec = linspace(35,85,100); 
tvec = linspace(3,5,100); 
[Tmat,tmat] = meshgrid(Tvec,tvec); 
Pout = F1(Tmat, tmat); 
[C,h] = contourf(Tvec,tvec,Pout);    
xlabel('IPTG Exposure Time (min)') 
ylabel('Total Culture Time (hr)') 
clabel(C,h)                            
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% Find the process points for the maximum yield pressure 
% Redefine the equation to a single variable form to be used for fmincon 
% Also remember to multiply by -1 to invert the equation (finding maximum) 
f = @(x) -1*(P(1) + P(2)*x(1) + P(3)*x(2) + P(4)*x(1).^2 + P(5)*x(2).^2); 
xo = [60 4.6]; 
lb = [35 3]; 
ub = [85 5]; 
[xout, feval] = fmincon(f,xo,[],[],[],[],lb,ub);   
hold on 
plot(xout(1,1),xout(1,2),'o') 
colormap autumn 
end 
Four Parameter Logistics Curve Fit for Cell Growth 
The entire growth curve for the 150 mL culture and the 1 L scale-up were obtained 
using OD600 measurements on a BioTek Synergy Neo plate reader. To translate the optimal 
growth and induction conditions found from the 150 mL culture to the larger, 1 L culture a 
four parameter logistics curve was fit to the data. The equation for this fit is: 
y=d+(a-d)/(1+(x/c)^b )  
 
Where y is the dependent variable (OD600 measurement), x is the independent 
variable (time), a and d are the maximum and minimum signal response variables 
respectively, and c and d are the inflection point and central slope of the sigmoidal curve 
respectively. The 150 mL growth data was fit with the four parameter model (R2 = 0.9992) 
and the optimal induction and harvest time points (216 and 276 min respectively) were found 
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to correspond to OD600 measures of 0.497 and 0.943 respectively. To translate this to other 
cell growth trends, we found the fractional measures of the cell growth span (difference in 
logistic parameters d and a) that correspond to these OD600 measures. Thus the optimal 
induction and harvest OD measures were found to be at 28 and 58.5% of the cell growth 
extent respectively. 
We then demonstrate how this optimal point could be used for larger reaction vessels, 
such as our 2.5 L flasks that can accommodate 1 L of culture each. This growth curve was fit 
by the same four parameter logistics model (R2 = 0.9993) and the corresponding time values 
at 28 and 58.5% of the growth extent were found to be 201 and 255 min respectively. These 
are then set as the optimal growth conditions for our larger reaction vessels. 
 
The Matlab code used for these fits is copied here: 
 
function plotGrowth_v2 
% Coded by NFR on 2.17.2018 
% This code plots the growth curve data for fitting 
% 
D1 = xlsread('150ml.xlsx'); 
% 150 ml data set 
M1 = mean(D1(:,2:4),2); 
T1 = D1(:,1); 
E1 = std(D1(:,2:4),[],2); 
errorbar(T1,M1,E1,'o') 
85 
[F1, gof] = createFit(T1, M1); 
hold on 
plot(F1) 
  
% Use fit parameters 
a = F1.a; 
b = F1.b; 
c = F1.c; 
d = F1.d; 
th = 4.6*60; 
Yharvest = d + (a - d)/(1+(th/c)^b); 
ti = 4.6*60-60; 
Yinduce = d + (a - d)/(1+(ti/c)^b); 
plot([0,th],[Yharvest,Yharvest],':r') 
plot([th,th],[0,Yharvest],':r') 
plot([0,ti],[Yinduce,Yinduce],':b') 
plot([ti,ti],[0,Yinduce],':b') 
xlabel('Time (min)') 
ylabel('OD600') 
hold off 
% Find what % of the span these 'optimal' points reside 
span = (d-a); 
Pi = (Yinduce-a)/span; 
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Ph = (Yharvest-a)/span; 
% Now use these points to FIT the larger reaction vessel 
% 1L data set 
D2 = xlsread('1L.xlsx'); 
M2 = mean(D2(:,2:4),2); 
T2 = D2(:,1); 
E2 = std(D2(:,2:4),[],2); 
figure 
errorbar(T2,M2,E2,'o') 
[F2, gof] = createFit(T2, M2); 
hold on 
plot(F2) 
% Find the optimal points for 1L culture 
% Use fit parameters 
a = F2.a; 
b = F2.b; 
c = F2.c; 
d = F2.d; 
span = (d-a); 
Yinduce = Pi*span+a; 
Yharvest = Ph*span+a; 
% Find the corresponding times: 
th = c*((a-d)/(Yharvest-d)-1)^(1/b); 
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ti = c*((a-d)/(Yinduce-d)-1)^(1/b); 
plot([0,th],[Yharvest,Yharvest],':r') 
plot([th,th],[0,Yharvest],':r') 
plot([0,ti],[Yinduce,Yinduce],':b') 
plot([ti,ti],[0,Yinduce],':b') 
xlabel('Time (min)') 
ylabel('OD600') 
hold off 
  
end 
  
function [fitresult, gof] = createFit(X, Y) 
%CREATEFIT(X,Y) 
%  Create a fit. 
% 
%  Data for 'untitled fit 1' fit: 
%      X Input : X 
%      Y Output: Y 
%  Output: 
%      fitresult : a fit object representing the fit. 
%      gof : structure with goodness-of fit info. 
% 
%  See also FIT, CFIT, SFIT. 
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%  Auto-generated by MATLAB on 17-Feb-2018 23:23:34 
  
  
% Fit: 'untitled fit 1'. 
[xData, yData] = prepareCurveData( X, Y ); 
  
% Set up fittype and options. 
ft = fittype( 'd+(a-d)/(1+(x/c)^b)', 'independent', 'x', 'dependent', 'y' ); 
opts = fitoptions( 'Method', 'NonlinearLeastSquares' ); 
opts.Display = 'Off'; 
opts.StartPoint = [0.52241020744548 0.140369177115148 0.356576574442871 
0.913375856139019]; 
  
% Fit model to data. 
[fitresult, gof] = fit( xData, yData, ft, opts ); 
  
% Plot fit with data. 
%{ 
figure( 'Name', 'untitled fit 1' ); 
h = plot( fitresult, xData, yData ); 
legend( h, 'Y vs. X', 'untitled fit 1', 'Location', 'NorthEast' ); 
% Label axes 
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xlabel X 
ylabel Y 
grid on 
%} 
end 
Response Surface Designed Experiment for Lyophilization 
A face centered cubic (FCC) designed experiment was used to determine the effects 
of dilution volume and number of passes through the continuous French press on the ultimate 
productivity of the cell free extract. The bounds on the two variables were 1 to 5 for number 
of passes and 1 to 3 for total dilution volume. The runs were generated and randomized via 
Matlab (Table S3.1). Dilution liquid, in this case, refers to the total volume of liquid added 
per gram of cells; for 1 mL, this is 1 mL of S30 buffer and no DI water. For 3 mL, it is 1 mL 
of S30 buffer and 2 mL water. In this case, the resulting lyophilized product will have the 
same salt content regardless of the start dilution volume. 
A large batch of cells was grown and distributed and amongst the three dilution levels 
in the DOE. When the tests were run, we found that the 1 mL dilutions were too viscous to 
consistently run through the French press; some of the cells would pass, some would get 
clogged and we would have to pass extra water or air through the system after turning the 
pump off, so collected samples were only partially lysed. These extracts were not tested. 
Furthermore two of the center point runs were not collected as there was not enough cells in 
the experiments; however there were three other runs at this point. 
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Table S3.2 – List of experiments and results from the FCC designed experiment for study of 
dilution volume and number of passes effects on cell extract productivity. 
 
 
The eight successful experiments were fit to a quadratic model, using Matlab code 
(copied below) and the resulting response model and goodness of fit parameters were 
reported: 
Linear regression model: 
    y ~ 1 + x1*x2 + x1^2 + x2^2 
 
Estimated Coefficients: 
                   Estimate           SE         tStat         pValue  
                   ________    ______    _______    _______ 
 
    (Intercept)          0          0        NaN        NaN 
    x1              9808.5     5504.7     1.7818    0.21672 
    x2              3142.9     7470.8     0.4207    0.71487 
    x1:x2            -3033       1636    -1.8539    0.20492 
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    x1^2           -671.82     598.72    -1.1221    0.37844 
    x2^2            443.57     2487.2    0.17834    0.87488 
 
 
Number of observations: 8, Error degrees of freedom: 3 
Root Mean Squared Error: 3.27e+03 
R-squared: 0.813,  Adjusted R-Squared 0.564 
F-statistic vs. constant model: 3.26, p-value = 0.18 
 
The partial model has an acceptable coefficient of determination however each of the 
model parameters have a high p-value. We determined the model was sufficient to show a 
general trend of decreased efficiency as dilution volume increased above 2 mL. Also, 
increased dilution also results in more drying time. As 2 mL dilution was sufficient to have 
good, reproducible passage through the French press, these conditions were used for the 
more detailed study on effect of number of passes through the French press. 
Matlab code used for this data analysis: 
function PlotDOE 
% Coded by NFR on 12.21.2017 
% Plots quadratic fit to response surface data 
  
D = xlsread('results.xlsx'); 
%                                    
mdl = fitlm(D(:,1:2),D(:,3),'quadratic')    
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P = mdl.Coefficients.Estimate; 
% X1 = number passes 
% X2 = dilution volume 
F1 = @(T,t) (P(1) + P(2)*T + P(3)*t + P(4)*T.*t + P(5)*T.^2 + P(6)*t.^2); % <-- 
NOTE: the wrong plot is given if the '.' notation is not used in the cross terms 
%                                   
% Make a contour plot 
Pvec = linspace(1,5,100); 
Dvec = linspace(2,3,100); 
[Pmat,Dmat] = meshgrid(Pvec,Dvec); 
Fout = F1(Pmat, Dmat); 
[C,h] = contourf(Pvec,Dvec,Fout);     
xlabel('Number of Passes') 
ylabel('Dilution Volume (ml)') 
clabel(C,h) 
Lyophilization Pictures 
Below are representative examples of lyophilized extract at different drying 
conditions. 
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Figure S3.2 - Extract after 1 hour of lyophilization. Total mass loss is equal to 48.5%. The 
presence of water is still obvious. 
 
 
Figure S3.3 - Extract after 2 hours of lyophilization. Total mass loss is equal to 91.5%. There 
are a couple noticeable traces of water. 
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Figure S3.4 – Extract after 4 hours of lyophilization. Total mass loss is equal to 94.8%. 
There is no noticeable water present. 
 
 
Figure S3.5 – Extract after 12 hours of lyophilization. Total mass loss is equal to 95.2%. 
There are no noticeable traces of water. 
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Figure S3.6 - Extract after 24 hours of lyophilization. Total mass loss is equal to 95.1%. 
There are no noticeable traces of water. 
 
 
Figure S3.7 - Extract after 48 hours of lyophilization. Total mass loss is equal to 96.2%. 
There are no noticeable traces of water. 
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Calibration Curve for sfGFP 
 
Figure S3.8 - Calibration curve of sfGFP RFU to mass concentration determined by adding 
purified sfGFP (quantified by Pierce 660 nm assay (Thermo Fisher)) in CFPS reaction 
mixture and measuring the RFU on plate reader at same gain setting as experiments. The 
linear regression gave an equation of y = 0.0048x - 6.1036 where x is the RFU value and y is 
the sfGFP concentration. The R2 value for the regression was 0.993. 
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CHAPTER 4.    RAPID PROTOTYPING OF PROTEINS: MAIL ORDER GENE 
FRAGMENTS TO ASSAYABLE PROTEINS IN 24 HOURS 
Modified from a manuscript submitted to Biotechnology and Bioengineering 
By Jared Lynn Dopp1, Samuel Michael Rothstein1, Thomas Joseph Mansell1, and 
Nigel Forest Reuel1 
1Iowa State University Chemical and Biological Engineering 
Jared conducted all experimentation and wrote all text. 
Samuel Rothstein ran all DNA gels. 
Dr. Tom Mansell provided edits and the time of his graduate student, Samuel 
Rothstein. 
Dr. Nigel Reuel edited the drafts and assisted in data analysis. 
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Abstract 
In this work, we present a minimal template design and accompanying methods to 
produce assayable quantities of custom sequence proteins within 24 hours from receipt of 
inexpensive gene fragments from a DNA synthesis vendor. This is done without the 
conventional steps of plasmid cloning or cell-based amplification and expression. Instead the 
linear template is PCR amplified, circularized, and isothermally amplified using a rolling 
circle polymerase. The resulting template can be used directly with cost-optimized, scalable-
manufactured E. coli extract and minimal supplement reagents to perform cell-free protein 
synthesis (CFPS) of the template protein. We demonstrate the utility of this template design 
and 24 hour process with seven fluorescent proteins (sfGFP, mVenus, mCherry, and four 
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GFP variants), three enzymes (chloramphenicol acetyltransferase, a chitinase catalytic 
domain, and native subtilisin), a capture protein (anti-GFP nanobody), and 2 antimicrobial 
peptides (BP100 and CA(1-7)M(2-9)). We detected each of these directly from the CFPS 
reaction using colorimetric, fluorogenic, and growth assays. Of especial note, the GFP 
variant sequences were found from genomic screening data and had not been expressed or 
characterized before, thus demonstrating the utility of this approach for phenotype 
characterization of sequenced libraries. We also demonstrate that the rolling circle amplified 
version of the linear template exhibits expression similar to that of a complete plasmid when 
expressing sfGFP in the CFPS reaction. We evaluate the cost of this approach to be 61 
USD/mg sfGFP for a 4 hr reaction. We also detail limitations of this approach and strategies 
to overcome these, namely proteins with post-translational modifications. 
4.1 Introduction 
Custom proteins are finding increased utility in advanced material fields such as gene 
delivery [1], biomaterials [2,3], enzyme design [4], active peptide design [5], and biosensors 
[6,7]. In each case, the ability to quickly screen the phenotypic behavior of each candidate in 
a large library of proteins is critical to down selecting to a smaller pool for expression 
optimization and purification. Often these candidates are random mutants, but recently 
powerful new approaches for in silico prediction results in a list of exact sequences to test 
[8]. In both cases the rate limiting step to screening proteins is the acquisition of the desired 
protein from in-house expression or vendors due to cost and time constraints. What is needed 
to advance this field is a time and cost-effective method to generate custom proteins from a 
list of candidate sequences with enough product titer to assay desired phenotype response 
(mechanical strength, activity, fluorescence, etc.) directly without investing time for 
purification and expression optimization. Efficient cell-free protein synthesis (CFPS) [9,10] 
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could provide the needed expression level and speed (2.3 mg/mL of protein demonstrated in 
12 hours [11]), however no current technique exists for expressing protein at assayable levels 
within one working day from receipt of mail-order gene fragments. Herein we provide details 
on an efficient, cost-effective, template design and five-step method to rapidly generate large 
amounts (mg) of genetic material, suitable for expression, from the small amount of custom 
gene fragment one receives from a vendor (500-1000 ng). We demonstrate its modular utility 
in expressing and assaying seven fluorescent proteins, three biocatalysts, one capture protein, 
and two active peptides, each in a 24-hour period. Furthermore, this new approach will allow 
any lab with a temperature-controlled mixer (e.g. Thermomixer) to produce a wide array of 
custom sequence proteins at a great reduction in price (>15x) over catalogue or contract 
research organization (CRO) options. We also detail current limitations we have found with 
this approach and strategies to overcome these limitations.  
We have developed a minimal template design and five-step process to generate large 
amounts of genetic material from a mail order gene fragment that is suitable for efficient 
CFPS (Fig 4.1). The minimalist template (Fig 4.1a, also Supplement 1) includes primer and 
digestion site sequences for amplification steps as well as sequences for the T7 promoter, 
ribosome binding site, start codon, stop codon and T7 termination site (total 288 bases) to 
achieve the needed transcription and translation. The desired protein sequence is inserted 
between the start and stop sequences, with typical total sequence length <1kb. The linear 
template is ordered as a gene fragment from vendor (7 U.S. cents per base pair at time of 
writing) and linear PCR is used to amplify the ordered template (116x) that contains flanking 
primer sequences paired to the common M13 forward and reverse sequencing primers 
(Supplement 1) (Fig 4.1b). During this step, mutations can be introduced using an error-
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prone DNA polymerase, or site-directed mutagenesis, to create a library of protein variants. 
Second, the linear template is digested near both ends using a restriction enzyme (HindIII) 
which results in self-affined, sticky ends (Fig 4.1c). Third, the digested DNA is diluted to 
50nM so the likelihood of self-association as a circular template is more likely than 
formation of linear concatamers (length to nearest neighbor < length of DNA chain); these 
circular products are repaired by T7 ligase (Fig 4.1d). Fourth, the circular template undergoes 
an overnight amplification (970x) using isothermal rolling circle amplification (RCA) (Fig 
4.1e) to amplify the library of variants to a concentration suitable for expression. This step 
can be terminated at 4-6 hours; however, we find it is most conveniently staged by starting 
this step at the end of the first work day (see clock inserts Fig 4.1). Finally, the following 
morning, the RCA template is added directly to a cell-free reaction for protein expression 
(Fig 4.1f-g). We found one example using RCA for E. coli based CFPS [12], but this was 
with cell-expressed and purified plasmids and not the fast minimalist circular template 
approach presented here.  
Purification and quantification of expressed protein can be done after this 24-hour 
period; however, it is beyond the scope of this project where the goal is to screen functional 
properties of the protein directly from the reaction immediately after expression. In this 
manner, the phenotypic value (activity, fluorescence count, cytotoxic strength, binding 
extent) is not tied to the produced protein quantity (as is typical), but rather the set amount of 
genetic template put into the reactions. We posit this is a better method of phenotypic 
screening for three reasons: 1) obviously the throughput of the screening is greatly improved 
if no quantification or purification is performed, 2) it selectively screens against proteins that 
are difficult to produce, and 3) traditional methods of measuring protein concentration in 
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CFPS obfuscate the real amount of protein present. For the second point, if one purifies and 
quantifies the produced protein (by adding an affinity-based tag (6x His, Strep, etc.) to the 
protein sequence), one might select a candidate that has a high phenotypic value per quantity 
of protein, but overall was produced poorly in CFPS. This would indicate a less robust 
sequence (e.g. slow folder) that may prove problematic during scale up to cell-based 
expression; herein we down-select based on overall phenotypic value benchmarked against 
other candidates with the same amount of starting template, thus screening for high 
phenotype measure and robustness. On the third point, protein quantification is typically 
done via incorporation of radiolabeled leucine to the expressed protein, spotting on filter 
paper, washing, drying, and analyzing with a scintillation counter [13]. While this method 
can prove to be effective for quantification of low amounts of proteins in complex CFPS 
mixtures [9,14,15], it does not distinguish between correctly folded, misfolded, and cleaved 
proteins. Since function is typically determined by structure (especially in the case of 
enzymes) this can provide a false normalization for the phenotype measure. 
To validate the utility of this rapid protein prototyping approach, we demonstrate 
expression and immediate assay of four classes of proteins with biotechnological impact: 
fluorescent reporters, various enzymes, capture proteins, and active peptides including 
sequences from genome databases that have putative characteristics. 
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Figure 4.1 – The minimal sequence design and five steps to express assayable amounts of 
protein from a mail-order gene fragment in 24 hours. a) Color coded representation of our 
minimalist template: black is primers, yellow regions are HindIII restriction enzyme digest 
sites, light green is the T7 promoter, purple is the ribosome binding site, dark green is the 
start codon, blue is the gene to be expressed, red is the stop codon, orange is the T7 
terminator, and white represents non-coding DNA to provide suitable spacing. For the five-
step process b) first, the template is suspended and amplified via linear PCR (1.6 h). c) Next 
HindIII digests the template ends (1 hr) and is heat inactivated (20 min). d) T7 ligase is then 
added to the digested template for circularization (1 hr). e) Dilute circular templates are then 
amplified overnight using rolling circle amplification (12-16 hr). f) The RCA templates are 
separated from any remaining dNTPs and are added to cell free extract and necessary 
reagents to support the CFPS reaction. g) Expression of sfGFP enables tracking of yield via 
fluorescent signal; 0.25 mg/ml is obtained in 4 hr. h) DNA gel comparing the different 
genetic constructs for sfGFP expression: whole plasmid, linear expression template, circular 
expression template, and rolling circle template (reading lanes left to right after ladder). 
 
4.2 Materials and Methods 
All linear expression templates (LETs) were ordered from Integrated DNA 
Technologies (Coralville, IA) and optimized for expression in Escherichia coli using IDT’s 
codon optimization tool (Supplement 1). LETs were suspended in nuclease free water at a 
stock concentration of 10 ng/µL. From this stock, 1 µL is added to 25ul GoTaq® Green 
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Master Mix (Promega), 21.4 µL ddH2O, and 1.3 µL of forward and reverse M13 primers 
each from IDT (0.5 µM final concentration) to make a final reaction volume of 50 µL in a 
PCR tube. These are replicated in three tubes total run with the following steps: 1) 95°C for 2 
min, 2) 95°C for 1 min, 3) 50°C for 1 min, 4) 72°C for 1 min, 5) go to step 2 and cycle 29 
times, 6) 72°C for 3 min, and 7) a 12°C hold. The resulting products are combined, cleaned, 
and concentrated using a Zymo purification kit (D4004), and eluted in 50 µL of water, 
yielding 70 ng/µL of PCR amplified template (116x amplification). The concentration was 
determined with 260/280 nm absorbance measurements with a Synergy NEO2 multi-mode 
reader (BioTek). The purified LETs were digested using HindIII-HF® (New England 
BioLabs) to create “sticky ends” by adding 5 µL of 10x buffer and 1 µL enzyme to 25 µL of 
the PCR amplified LET template and cycling for 1 hr at 37°C. The HindIII enzyme was then 
heat inactivated by holding at 80°C for 20 minutes. Digested templates were combined with 
T7 Ligase (New England BioLabs) at 25°C for 1 hr in the following amounts: 25 µL digested 
DNA, 25 µL T7 2x buffer, and 1 µL T7 enzyme. The circular expression templates (CETs) 
were then purified with the Zymo purification kit, eluted with 50 µL water, providing a 
typical yield of 30 ng/µL. Rolling circle amplification was carried out using a TempliPhi (GE 
Healthcare) kit. This works well with circular templates at the 10 pg/µL concentration, so the 
CET is diluted 1000x and then added according to the kit instructions (1 µL template DNA, 5 
µL sample buffer, 5 µL reaction buffer, 0.2 µL enzyme) and is replicated in four reaction 
tubes. These run overnight (12-14 hr) at 30°C. The resulting, viscous mixture is diluted by 
adding 14 µL ddH2O per tube (total volume 25 µL) and all are then combined, and purified 
with the Zymo kit, eluted with 50 µL of water with a typical final RCA template 
concentration of 70 ng/µL. 
104 
All cell-free reactions were conducted at 37°C in volumes of 15 µL using the 
following: 30% v/v E. coli extract (produced according to our previously published work on 
scalable extract10), 10 ng/µL of RCA DNA, 6 µL T7 S30 High Yield Premix (Promega), and 
double distilled water. Lyophilized extract was reconstituted with double distilled water 
according to previous experiments H2O (mL) = (mass of lyophilized extract (g))(1.5 
mL/0.094 g) [10].  
Fluorescent proteins sfGFP, mVenus, and mCherry were expressed in a 384 well 
plate covered with a colorless film (Axygen) at 37°C and 237 RPM for 4 hours. The 
reactions were monitored in a plate reader (BioTek Synergy Neo) with a fluorescence 
reading every 5 minutes. sfGFP and mVenus were detected with an excitation/emission of 
485/528 nm, a bandpass window of ±20, and a gain of 61. mCherry was detected with an 
excitation/emission of 587/610 nm, a bandpass window of ±10, and a gain of 100. The optics 
position was set to read the bottom of the plate. A calibration curve (Supplement Figure 
S4.4) was used to quantify sfGFP. This curve was generated using a BSA standard in a 
Pierce 660 nm assay (Thermo Fisher). The four uncharacterized GFP variants were expressed 
identically to other fluorescent proteins but were screened using two different 
excitation/emission spectra. The spectra corresponded to native GFP 400/509 nm with a 
bandpass window of ±20 and sfGFP 485/528 nm with a bandpass window of ±20. Because 
we did not know the quantum efficiency of these possible proteins, we maintained a gain of 
61 on our plate reader. 
CAT, PrChi-cat, subilisin were expressed in a 384 well plate, covered with a colorless 
film, at 37°C and 300 RPM for 6 hours. Reactions took place in a ThermoMixer Type C 
(Eppendorf). The protocol used to assay CAT was based off the molar extinction coefficient 
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of 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB). The assay was performed in a colorless U-
bottom 96 well plate with 180 µL of 100 mM Tris pH 7.8, 6.7 µL of 2.5 mM DTNB in Tris, 
6.7 µL of acetyl CoA, and 3.3 µL of 0.3% w/v chloramphenicol dissolved in 10% v/v 
methanol. The mixture was incubated at 25°C until the absorbance at 410 nm stabilized. 
After the readings became stable, triplicates of finished CFPS reactions, with CAT 
expression and with no DNA (background control), were added at a volume of 3.3 µL. 
Absorbance at 410 nm was taken every 20 seconds for 5 minutes using a plate reader at a 
temperature of 25°C. The maximum slopes of the CAT reactions and control were used to 
compute the activity (U/ml) as shown in the “Enzymatic Assay of Chloramphenicol 
Acetyltransferase” Sigma Aldrich protocol, where one unit (U) will convert 1.0 nanomole of 
chloramphenicol and acetyl-CoA to chloramphenicol 3-acetate and CoA per min at pH 7.8 at 
25 °C. PrChi-cat activity was determined using the fluorogenic substrate 4-
methylumbelliferyl-β-D-N,N’,N’’-triacetylchitotrioside (MUF-triNAG) (Cayman Chemical). 
The assay was conducted in a black walled, flat bottom 384 well plate with 75 µL of 200 mM 
potassium phosphate buffer pH 7.0 and 10 µL of 1 mM MUF-triNAG in DMSO. The Buffer 
and substrate were incubated for 15 minutes at 37°C before addition of the samples. Upon 
addition of 15 µL of sample (PrChi-cat containing reaction or null reaction), fluorescence 
measurements were taken every 30 seconds for 15 minutes at an excitation/emission of 
360/445, a band pass window of ±20, and a gain of 100. Subtilisn was assayed in a colorless 
U-bottom 96 well plate using 94 µL of double stilled H2O and 1 µL of N-Succinyl-Ala-Ala-
Pro-Phe p-nitroanilide (Sigma Aldrich). Either 5 µL of subtilisin CFPS reaction, or null 
reaction was added, and absorbance measurements were taken at 410 nm every 10 seconds 
for 5 minutes at a temperature of 25°C. 
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HisPur™ cobalt spin columns (Thermo Fisher) were used to identify anti-GFP. The 
nanobody containing reaction was incubated on the column for 30 minutes at 4°C and 
washed 3 times with the provided wash buffer. Then, 250 µL of E. coli extract containing 
GFP was added to the column and incubated for 30 minutes at room temperature. The 
column was then washed 3 times and 2 bed volumes of wash buffer was added for hydration. 
The columns were shaken to homogenize the beads and 15 µL was transferred, in triplicates, 
to a 384 black walled well plate for fluorescence analysis. Fluorescent intensity was 
measured at an excitation/emission of 488/510 nm with a ±10 nm band pass window. 
AMPs were expressed using the aforementioned reaction conditions except the 
reaction was stirred at 1200 RMP and ran for only 2 hours to avoid degradation by 
endogenous proteases. The CFPS reaction also used a DNA concentration of 15 ng/µL. E. 
coli (MG1655) and B. subtilis (JH642) were grown in 5 mL LB overnight cultures and 
diluted to an OD600 of 0.22 and 0.26 respectively. The bacteria were then diluted to 104 
cells/mL and added to a colorless 96 well U-bottom plate in 10 µL aliquots. 10 µL of AMP 
CFPS reaction was then added (BP100 for E. coli and CM15 for B. subtilis) as well as 10 µL 
of mineral oil to reduce evaporation. The plate was incubated in a plate reader at 37°C for 
11.5 hours with OD600 measurements taken every 30 minutes while being stirred at 237 
rpm. 
4.3 Results and Discussion 
4.3.1 Fluorescent Proteins 
As an initial demonstration of this technique, gene fragments for three established 
fluorescent proteins were tested due to the convenience of gauging protein expression 
through fluorimetry (Fig 4.2). First, the super-folder green fluorescent protein (sfGFP) 
sequence was selected for its fast-folding kinetics and reliability presented in previous CFPS 
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works [9,10]. Additionally, two other fluorescent proteins with slower folding kinetics, and 
lower quantum efficiency (mVenus and mCherry) [16] were also selected to demonstrate the 
general applicability of this technique. In all cases, the fluorescent signal from the proteins 
was observed using real time monitoring in a plate reader during CFPS expression. Of 
special interest, these kinetic curves corroborate previously presented findings that compare 
1) the brightness of various fluorescent proteins in which mVenus was found to be brightest, 
followed by sfGFP, then mCherry and 2) folding time to maximum fluorescence with sfGFP 
reaching this point first, followed by mVenus, then mCherry [16]. We also compared sfGFP 
expression levels from each of the genetic templates produced in this work (plasmid, linear, 
circular, and rolling circle). These templates were tested on a molar basis (Supplement Figure 
S4.1) and a mass basis (Supplement Figure S4.2) and showed no significant difference 
between plasmid expression and RCA expression.  
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Figure 4.2 - Fluorescent proteins sfGFP, mVenus, and mCherry (n=5, shaded areas show one 
standard deviation) as observed dynamically from their fluorescence signal during the CFPS 
reaction time frame (sfGFP and mVenus Ex/Em was 485/528 nm and mCherry was 
587/610). 
 
Additionally, sequences for four sequences were identified from the UNIPROT 
database that were uncharacterized (never expressed) and had a high level of sequence 
similarity to native green fluorescent protein (GFP). These are A0A125NTU3_HYPSL, 
K0NYR4_9CAUD, A0A2S8V8C2_9BACI, and A0A2V2QJP9_9ACTN with 97.9, 97.1, 
99.2, and 98.7 percent sequence homology to GFP (Supplement Figures S4.6-S4.9). These 
were especially selected as they were determined solely by archived genome sequences of 
Hyphomicrobium sulfonivorans, Escherichia virus RB43, Bacillus sp. MYb78, and 
Streptomyces sp. ZEA17I, respectively. Additionally, a larger, putative fluorescent protein 
sequence, A0A2P6SAD1_ROSCH, from Rosa chinensis was selected (Supplement Figures 
S4.4 and S4.5). These all had had ‘uncharacterized’ annotations in the UNIPROT database. 
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We ordered the minimal sequences and expressed using the 24-hour method presented here 
and monitored their fluorescence using two emission/excitation windows (sfGFP range 
485/528 nm (Fig 4.3) and native GFP range 400/509 nm (Supplement Figure S4.3)). The four 
close homology sequences exhibited high levels of fluorescence (up to 25% level of sfGFP as 
seen Fig 4.3) whereas the larger, putative sequence had very low levels of fluorescence (<3% 
of sfGFP level as seen in Supplement S4-S5). Of interest, we observe no correlation between 
the level of homology and the level of fluorescence; for example, K0NYR4_9CAUD has 2X 
the fluorescent level as A0A2S8V8C2_9BACI, but has 7 residue differences instead of 2 
residues from WT (wild-type) GFP. This indicates possible interacting effects of amino acids 
in the folded protein and greater impact of certain mutation sites [17,18]. This data set helps 
illustrate the proposed use of this technique for rapid phenotypic screening of sequences 
found by genome discovery, such as design rules for fluorescent reporter proteins. 
 
Figure 4.3 – Time course of fluorescence (Ex/Em was 485/528 nm) observed from four 
previously uncharacterized proteins being expressed in CFPS 24 hours after receipt of mail 
order template. Sequences have >90% homology with wild type GFP and were obtained from 
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archived whole organism genome screens (names from Uniprot database and level of 
homology listed in legend). For each sequence n=5 and shaded areas show one standard 
deviation. 
 
4.3.2 Enzymes 
Enzymes are another class of industrially-relevant proteins with convenient methods 
of detection. We first selected a model enzyme, chloramphenicol acetyltransferase (CAT), 
the enzyme responsible for chloramphenicol resistance in E. coli. CAT expression has been 
demonstrated previously via plasmid-based CFPS [15]. We expressed three 15µL reactions 
containing RCA amplified CAT template and three control reactions without template in 24 
hours and then added them after expression (no purification) to an established assay by Shaw 
[19] to measure CAT units (U) of activity (the rate (nmol/min) of conversion of 
chloramphenicol and acetyl-CoA to chloramphenicol 3-acetate and CoA at pH 7.8 at 25 
°C)(Fig 4.4a). We found that each reaction produced CAT at levels comparable to 
commercially expressed products (5000 to 6000 U/ml raw CFPS mix). Next, we attempted to 
produce two hydrolases that had not been previously established in CFPS, to again determine 
how amenable this new technique was to unproven sequences. First we selected the catalytic 
domain of a class IIIb chitinase from the fern Pteris ryukyuensis (PrChiA-cat) which had 
been previously expressed in E. coli and had measurable endochitinase activity [20]. A class 
IIIb chitinase was selected as they have no disulfide bonds which makes them more 
straightforward to express in vitro (see limitations discussion below). The template was 
ordered, amplified, and the expression product was screened using a fluorogenic substrate, 4-
methylumbelliferyl-β-D-N,N’,N’’-triacetylchitotrioside (MUF-triNAG – insert Fig 4.4b) for 
detection. We observed a significant increase in activity from the chitinase containing CFPS 
mix whereas the signal from the CFPS reaction containing no template (null sample) 
decreased (Fig 4.4b) over the assay time of 15 minutes. Last we tested a native subtilisin 
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(nSBN) sequence [21] that had not been previously attempted in CFPS. Again, we inserted 
the codon optimized sequence in the minimal LET design (Fig 4.1a), ordered from vendor, 
amplified and expressed in 24 hours. We then directly assayed the CFPS mixture in an 
established protease assay based on the hydrolysis of N-Succinyl-Ala-Ala-Pro-Phe p-
nitroanilide (Fig 4.4c insert) and found nSBN cleaved the substrate to increase the 
colorimetric signal and the null reaction (no template CFPS reaction) drifted below the 
baseline indicating no cleavage. 
 
Figure 4.4 - Three biocatalyst proteins, a) chloramphenicol acetyltransferase (CAT) activity 
as observed with a colorimetric assay kit, where 1 unit (U) can change 1.0 nanomole of 
chloramphenicol and acetyl-CoA to chloramphenicol 3-acetate and CoA per min at pH 7.8 at 
25 °C , b) a truncated chitinase sequence (PrChi-cat) as observed by degradation of a 
fluorogenic substrate (MUF-triNAG, insert) (n=3), and c) native subtilisin as observed by 
degradation of a colorimetric substrate (N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide, insert) 
(n=3). 
 
4.3.3 Nanobody 
Capture proteins are another broad class of proteins with immediate biotechnological 
impact [22,23]. As a representation of this class, we demonstrated expression of an anti-GFP 
nanobody in 24 hours, that had previously been expressed using plasmid based CFPS [24]. 
This nanobody has been shown empirically to bind green fluorescent protein [25]. We added 
a 6xHis-tag at the C-terminus of the anti-GFP sequence for easy purification and detection. 
Functional nanobody expression was confirmed by incubating the post reaction mixture with 
cobalt agarose chromatography beads, washing, and then adding GFP (Fig 4.5 insert) from an 
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unpurified, clarified E. coli extract. The anti-GFP containing sample had a 59-fold increase in 
signal over the null using a standard plate reader (Fig 4.5). 
 
Figure 4.5 - An example of a capture protein was expressed (e) using a GFP nanobody 
sequence, in which cobalt-agarose beads are incubated with the CFPS expressed his-tagged 
anti-GFP nanobody, washed, exposed to GFP (insert shows structure from PDB file 1GFL), 
washed and fluorescence of captured GFP is compared to beads incubated under same 
conditions with the null reaction (n=3). 
 
4.3.4 Antimicrobial Peptides 
One advantage of CFPS over cellular expression systems is the ability to produce 
proteins that may be toxic to the industrial host. We demonstrate this through the expression 
of antimicrobial peptides (AMPs). These are used by organisms as a natural defense against 
infection by membrane disruption [26]. AMPs have previously been expressed using a 
lyophilized E. coli extract and a plasmid-based, cell-free system [24]. Using our minimal 
template technique we expressed BP100 and CA(1-7)M(2-9) which have documented 
activity against E. coli and B. subtilis growth cultures respectively [24], and found that CFPS 
reactions with AMPs added to bacterial cultures exhibited growth inhibition as reported by 
their OD600 absorption curves (Fig 4.6). 
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Figure 4.6 - An example of membrane-disrupting peptides was performed (f) expressing 
broad spectrum antimicrobial peptides in CFPS and adding to E. coli and B. subtilis 
fermentations showing growth inhibition. 
 
4.3.5 Advantages and Limitations: Time, Cost, and Modularity 
When comparing this in vitro method to established in vivo techniques, one has to 
weigh the advantages and limitations in time, cost, and modularity (ability to express a wide 
variety of proteins). It is also important to note that these comparisons are made for 
prototyping and scouting proteins, not for production. In vivo methods will typically out 
produce in vitro methods unless the target of interest is difficult to express or cytotoxic, such 
as the subtilisin and BP100 expressed in this work. The steps of prototyping a protein for 
phenotypic testing with traditional, cell-based methods are summarized in Table 4.1 and 
presented briefly here. After receipt of the template from a vendor there is a 2-4 hr PCR step 
(depending on the size of the genetic template, typically 1-4 kb), a 20 min DNA gel to check 
for purity, 2.5 hrs of digestion and ligation steps (expanded in Table 4.1), DNA a 1.5 hr 
transformation into competent E. coli cells, an overnight growth on a plate, a 2-4 hr colony 
PCR step, another 20 minute DNA gel, possible hits sent for sequencing overnight with 
overnight growths can run in parallel with sequencing, a final growth for protein expression 
that will depend on induction time and temperature, and finally a 30 minute centrifugation 
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step. The cell-based method takes 2-3 days, if everything works correctly. If the initial DNA 
gel shows too much smearing, the amplification needs to be run again. The transformation 
will also need to be attempted again if the second DNA gel does not indicate the gene of 
interest in any of the colonies present on the plate. Any protein that causes a visual change to 
the cell, such as fluorescent reporter proteins, can be readily tested. However, for other 
proteins of interest (e.g. enzymes) have no visual identifier, and a transmembrane assay 
needs to be developed or the cells are carefully lysed and tested. This process is conducted 
for each gene of interest and would need to be parallelized for a larger library. Likely, the 
cost of reagents for in vivo expression is lower than that of in vitro on a per mass basis (as 
yields are often higher). However, at the prototyping phase, when only a small amount of 
candidate protein is needed to test phenotype quality, this advantage is diminished by the 
time required to create and test each protein (and the limit of sequences that can be run in 
parallel). 
The time required to express protein from this paper’s in vitro technique is easily kept 
within 24 hours, if one has already grown and processed the cell extract or obtained this from 
a commercial vendor. Our previous work enables scalable, lyophilized extract preparation 
that preforms as well as smaller-scale, tip-sonicated methods and outperforms commercial 
extract [10]. Moreover, it can be grown in >100 g (well cell mass) batches that are 
conveniently lyophilized, stored, and easily sourced to requesting partners. 
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Table 4.1 - Steps and time required to prototype a protein in vivo using traditional cloning 
methods. 
Step Time 
PCR of gene fragment from vendor 2-4 hr 
Gel electrophoresis to isolate fragment 20 min 
Digestion of plasmid and insert DNA 1 hr 
Dephosphorylation of plasmid DNA 30 min 
Gel electrophoresis of digested insert and plasmid DNA 20 min 
Gel extraction of digested insert and plasmid DNA 20 min 
Ligation of plasmid and insert DNA and heat inactivation of ligase 20 min 
Transformation of plasmid into competent cell line 1.5 hr 
Plate growth of transformed cells overnight 
Pick colonies; perform colony PCR of transformed cells 2-4 hrs 
Gel electrophoresis to prep for sequencing 20 min 
Overnight growth of candidate cells for freezer stock* overnight 
Sequencing of candidate cells* overnight 
Grow cells for protein expression varies 
Centrifugation of cell pellet 30 min 
Lysis and prep for phenotype assay varies 
* Denotes steps that can be run in parallel with one another 
 
The cost of protein prototyping from this in vitro method is competitive especially 
when one uses scalable extract preparation techniques as noted above [10] and minimal 
reagent recipes [14,27–29]. When analyzing the cost per gram of sfGFP produced 
(Supplement Figures S4.10), we found a minimalist reagent mix, like those used in previous 
works [10,29], produced sfGFP at 110 µg/mL (found by fluorescence calibration curve Fig 
S4.12) after 4 hours of expression which resulted in $61/mg sfGFP. When using a vendor kit, 
such as Promega T7 S30 High-Yield with the minimalist, circular templates a 64% decrease 
in protein yield (40 µg/mL) was observed (Supplement Figure S4.11) which resulted in a 
135-fold increase in cost ($8,265/mg sfGFP) (Supplement Figure S4.13). Both costs include 
the DNA amplification, with >80% of the in-house cost going to commercial rolling circle 
reagents (another target for price reduction). The Promega kit cost was found by scaling 
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down their recommended reaction volume from 50 to 15 µL and using their recommended 
higher extract concentration per reaction (36% v/v opposed to our 30% v/v). The cost 
estimate for in-house extract preparation comes from methods used in our previous work [10] 
but the cost is limited to the media and buffer components required to grow and lyse the 
cells. Labor costs and capital costs (shaker, French press, cells, etc.) are not included in our 
estimate as the extract can be grown and processed in large batches with minimal personnel 
interaction, such that these additional costs are insignificant compared to the reagent costs 
per mass of protein produced. The referenced work details our optimized methods as well as 
the time commitments required for production based on what mass of cells is harvested.  
To further investigate our finding of low yield from an RCA minimal template using 
the commercial kit, we benchmarked it against a pJL-1 plasmid [9] with sfGFP that had 
undergone rolling circle amplification, and the same pJL-1 plasmid amplified from cellular 
production. We found that the kit works very well with the plasmid alone but exhibits ~62% 
decrease in expression when using template that has gone through rolling circle 
amplification. However, the pJL-1 that had undergone RCA performed significantly better 
than the minimal template that had undergone RCA. This may be due to the strain of E. coli 
used in the commercial extract (not disclosed) and might be overcome by using a commercial 
kit that is optimized for linear DNA, such as Promega’s S30 System for Linear Templates.  
In general, a commercial kit can be a quick source for prototyping proteins for 
functional screening if the library size of proteins is small. Commercial kits also have the 
advantage of little to no prior training in biology and would only require a thermocycler to 
perform the proposed method outlined in this work. For larger libraries of proteins, costs can 
be significantly reduced for larger libraries of proteins by manufacturing extract and CFPS 
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supplement mixes in-house. Creating a supplement mix is a straightforward process and the 
recipes are available in the cell-free literature [9,11,30,31]. The biggest hurdle for labs with 
no biology infrastructure would be extract preparation, which can be addressed through the 
ease and transportability of scalable extract production [10]. 
This method shares some limitations with that of traditional CFPS. Cell-free 
expression with E. coli extract cannot form disulfide bonds between cysteine residues 
without changing the redox potential. Disulfide bonding is commonly achieved through the 
pretreatment of extract with iodoacetamide, the addition of glutathione, and the addition of 
disulfide bond isomerase C (DsbC) [29]. However, this limitation can be overcome by 
mutating cysteines involved with disulfide bonding as long as the bonds are not necessary for 
protein structure and function [32]. CFPS is also incapable of independent glycosylation due 
to the lack of endogenous glycosyltransferases but recent work has shown that these proteins 
can be expressed with CFPS and used to glycosylate proteins in vitro [33]. Purification, if 
desired, can also prove to be an issue in cell-free systems. This can be overcome, depending 
on the desired purity, through multiple tagging methods such as: his-tag, strep-tag, FLAG-
tag, or SpyTag. It is also possible to attach the desired protein to a less soluble peptide (e.g. 
elastin-like peptides) via a degradable linker, TEV for instance. 
This procedure provides a much faster approach to genetic template amplification 
than traditional plasmid-based approaches, with one drawback being template purity. As the 
template undergoes many enzymatic ligations and transfers, there are many opportunities for 
random errors. Also, a longer gene fragment is more likely to exhibit amplification errors 
than a shorter fragment. A major gene vendor, IDT, recommends a high-fidelity polymerase 
for fragments ≤ 1 Kb and does not recommend amplification for fragments > 1 Kb. We have 
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found a lower fidelity polymerase (Taq) to be sufficient in this initial work (e.g. we can make 
and measure proteins). Other variables that can improve amplification is the optimization of 
primers and thermocycling conditions; we used the common M13 forward and reverse 
sequencing primers because of their low cost and stock availability from vendors. The 
heterogeneity observed in the amplicon lengths (spread on the gel in Fig 4.1g) could be 
reduced by optimizing PCR conditions (Mg2+ concentration, annealing temperatures, and 
primer sequence) [34].In more common practice, this heterogeneity from fragment 
amplification is mitigated by inserting the sequence in a plasmid containing a selection agent 
(e.g. antibiotic resistance), transforming the sequences into cells, and then picking cells that 
overcome the selection agent. The sequence is then checked via sequencing and the 
confirmed cell is banked as a frozen glycerol stock. In the procedure outlined by this work, 
any heterogeneity caused by amplification error is perpetuated at each step. This can be 
visualized on a gel (Fig 4.1g) which shows template length heterogeneity after the linear 
PCR, circularization, and RCA steps; notwithstanding this heterogeneity, the expression of 
custom proteins from this method can still be incredibly useful in screening applications 
where the best candidates (highest activity or binding) could be quickly identified and then 
the dominant template sequence could be determined via sequencing. It should be noted that 
once a desired candidate has been discovered, it should be cloned into a plasmid vector and 
transformed into a cell for in vivo production and purification optimization. While our 
method can be a powerful tool for discovery, it cannot compare with in vivo expression 
levels (unless the desired protein is cytotoxic or elsewise difficult to express in cells). 
In conclusion, we have developed minimal DNA constructs and amplification 
methods that allow CFPS to be used as a tool for generating libraries of custom proteins in a 
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time and cost-effective manner for phenotypic screening. This method results in assayable 
levels of protein within 24 hours of receiving a mail order template. This could lead to 
drastically improved candidate discovery times when coupled with in silico predictions [8], 
site directed mutagenesis to expand the library, and expression in micro reactors [35]. This 
would enable quick identification of the best candidates before using traditional in vivo 
techniques for high level production. Furthermore, another benefit of this method is the lack 
of specialized equipment, and experience needed to prototype new proteins. This allows 
easier access to protein engineering in labs that are not equipped for specialized biological 
research. 
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Appendix 
Linear Expression Templates 
Below are the genetic templates used CFPS expression. All sequences were optimized 
for Escherichia coli using IDT’s codon optimization tool. The sequences are color coded 
according to the following key: 
T7 Promoter – T7 Promoter 
 
RBS – Ribosome binding site 
 
Start – Start codon 
 
Protein Sequence – Gene coding for protein 
 
Stop – Stop codon 
 
T7 Terminator – T7 Terminator 
 
Circularization site – HindIII Digest 
 
Primer Sequences – Primer sequences 
sfGFP – 999 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGAGCAAAGGTGAAGAACTGTTTACCGGCGTTGTGCCGATTCT
GGTGGAACTGGATGGCGATGTGAACGGTCACAAATTCAGCGTGCGTGGTGAAGG
TGAAGGCGATGCCACGATTGGCAAACTGACGCTGAAATTTATCTGCACCACCGG
CAAACTGCCGGTGCCGTGGCCGACGCTGGTGACCACCCTGACCTATGGCGTTCA
GTGTTTTAGTCGCTATCCGGATCACATGAAACGTCACGATTTCTTTAAATCTGCA
ATGCCGGAAGGCTATGTGCAGGAACGTACGATTAGCTTTAAAGATGATGGCAAA
TATAAAACGCGCGCCGTTGTGAAATTTGAAGGCGATACCCTGGTGAACCGCATT
GAACTGAAAGGCACGGATTTTAAAGAAGATGGCAATATCCTGGGCCATAAACTG
GAATACAACTTTAATAGCCATAATGTTTATATTACGGCGGATAAACAGAAAAAT
GGCATCAAAGCGAATTTTACCGTTCGCCATAACGTTGAAGATGGCAGTGTGCAG
CTGGCAGATCATTATCAGCAGAATACCCCGATTGGTGATGGTCCGGTGCTGCTGC
CGGATAATCATTATCTGAGCACGCAGACCGTTCTGTCTAAAGATCCGAACGAAA
AACGGGACCACATGGTTCTGCACGAATATGTGAATGCGGCAGGTATTACGTGGA
GCCATCCGCAGTTCGAAAAATAATAAGTCGACCGGCTGCTAACAAAGCCCGAAA
GGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG
GGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAA
CTTCGGGTCATAGCTGTTTCCTG 
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mVenus – 999 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGAGCAAAGGCGAAGAACTGTTCACGGGTGTGGTTCCGATCCT
GGTTGAACTGGATGGCGATGTGAACGGTCATAAATTTAGCGTGTCTGGTGAAGG
CGAAGGTGATGCGACCTACGGCAAACTGACGCTGAAACTGATTTGCACCACGGG
TAAACTGCCGGTTCCGTGGCCGACCCTGGTGACCACGCTGGGTTATGGTCTGATG
TGTTTCGCACGTTACCCGGATCACATGAAACGCCATGATTTCTTTAAATCTGCGA
TGCCGGAAGGCTATGTGCAGGAACGTACCATCTTTTTCAAAGATGATGGTAACTA
CAAAACCCGCGCGGAAGTTAAATTTGAAGGCGATACGCTGGTGAACCGTATTGA
ACTGAAAGGTATCGATTTCAAAGAAGATGGCAATATTCTGGGTCACAAACTGGA
ATACAACTACAACAGTCATAACGTGTACATTACCGCCGATAAACAGAAAAACGG
TATCAAAGCAAACTTCAAAATCCGTCACAACATCGAAGATGGCGGTGTTCAGCT
GGCCGATCATTACCAGCAGAACACCCCGATTGGCGATGGTCCGGTGCTGCTGCC
GGATAATCATTATCTGAGTTACCAGAGCAAACTGTCTAAAGATCCGAATGAAAA
ACGCGATCACATGGTTCTGCTGGAATTTGTGACCGCGGCCGGCATTACGCATGGT
ATGGATGAACTGTATAAATAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGG
AAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACT
TCGGGTCATAGCTGTTTCCTG 
 
mCherry – 993 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGGTGAGTAAAGGCGAGGAGGACAATATGGCGATCATCAAAG
AGTTCATGCGCTTCAAAGTCCACATGGAAGGCAGCGTTAATGGTCACGAGTTCG
AAATTGAGGGCGAAGGCGAAGGTCGTCCGTATGAGGGTACACAGACCGCTAAAC
TGAAAGTCACGAAAGGTGGTCCACTGCCATTTGCTTGGGATATTCTGAGCCCACA
GTTCATGTATGGCTCCAAAGCCTATGTGAAACATCCGGCCGATATTCCGGACTAT
CTGAAACTGAGCTTCCCTGAAGGGTTCAAATGGGAACGTGTGATGAACTTTGAG
GATGGTGGTGTTGTGACAGTGACACAGGATTCTAGCCTGCAAGACGGTGAGTTC
ATCTATAAAGTGAAACTGCGTGGCACGAATTTTCCGAGTGATGGCCCGGTTATGC
AGAAAAAAACGATGGGTTGGGAGGCCTCTAGTGAGCGTATGTATCCAGAAGATG
GCGCTCTGAAAGGCGAAATCAAACAGCGTCTGAAACTGAAAGATGGTGGCCACT
ATGATGCCGAAGTGAAAACCACGTATAAAGCCAAAAAACCTGTCCAACTGCCTG
GTGCCTATAACGTTAACATCAAACTGGACATCACCTCACACAATGAGGACTATA
CGATCGTGGAGCAGTATGAGCGTGCTGAAGGACGTCATTCTACCGGTGGTATGG
ATGAGCTGTATAAATAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGAAGC
TGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCT
AAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTTCGGG
TCATAGCTGTTTCCTG 
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A0A125NTU3_HYPSL – 1002 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGCTTAGCAAAGGTGAGGAATTATTTACAGGAGTTGTCCCCAT
ATTAGTAGAGCTTGATGGGGACGTGAACGGTCACAAATTTTCAGTCAGTGGGGA
GGGTGAGGGGGACGCTACTTATGGGAAGTTGACCCTTAAATTCATATGTACTACT
GGCAAGCTGCCCGTACCGTGGCCGACATTGGTCACGACATTCGGGTATGGACTG
CAGTGCTTTGCTCGTTATCCTGACCATATGAAGCAACATGATTTCTTTAAATCTGC
TATGCCGGAGGGCTACGTGCAAGAACGGACAATTTTCTTTAAAGACGACGGTAA
CTACAAAACTCGGGCTGAGGTAAAGTTTGAGGGAGATACACTTGTCAATCGCAT
AGAGCTGAAAGGAATAGATTTCAAGGAAGACGGTAACATTCTGGGACATAAATT
GGAATACAATTACAACAGCCACAACGTCTATATAATGGCAGATAAGCAAAAAAA
CGGTATTAAGGTGAACTTTAAGATCCGCCACAACATTGAGGATGGCTCCGTTCAA
TTGGCAGACCATTACCAGCAGAATACTCCAATCGGTGACGGTCCCGTATTATTAC
CGGACAACCACTACCTGTCCTATCAATCAGCTTTGTCTAAAGACCCGAATGAAA
AAAGAGATCACATGGTTTTGCTGGAGTTTGTTACAGCCGCGGGAATAACTTTAGG
GATGGATGAACTTTACAAATAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAG
GAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGG
GCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAAC
TTCGGGTCATAGCTGTTTCCTG 
 
 
K0NYR4_9CAUD – 999 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGAGCAAGGGGGAGGAGTTATTTACCGGTGTGGTACCTATTCT
TGTAGAACTTGATGGAGACGTTAACGGTCATAAATTCAGCGTGAGTGGAGAAGG
CGAGGGAGACGCGACATACGGCAAACTTACGTTAAAATTTATCTGTACAACAGG
GAAGTTGCCAGTACCTTGGCCTACTTTAGTAACAACGCTTACTTATGGCGTCCAA
TGCTTTAGCCGGTACCCTGATCATATGAAACGTCACGATTTCTTTAAGAGTGCCA
TGCCCGAAGGATATGTACAAGAACGTACTATTAGTTTCAAGGACGACGGCAATT
ACAAAACACGCGCGGAAGTGAAATTCGAGGGAGATACGTTGGTAAACAGAATC
GAACTGAAAGGCATTGATTTTAAGGAGGATGGTAATATATTAGGCCACAAGTTA
GAATATAATTATAATTCGCATAATGTCTACATAACAGCGGATAAGCAGAAGAAT
GGTATCAAAGCAAATTTCAAAATTCGTCATAACATCGAAGACGGTAGTGTCCAA
CTGGCTGATCATTATCAGCAGAACACTCCAATCGGTGACGGACCTGTTTTGCTGC
CTGACAACCATTATTTGTCGACTCAGTCTGCCCTGCTGAAAGATCCGAATGAGAA
AAGAGATCACATGGTCCTGCTTGAGTTCGTAACGGCAGCAGGGATAACCCACGG
GATGGACGAACTGTATAAGTAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAG
GAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGG
GCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAAC
TTCGGGTCATAGCTGTTTCCTG 
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A0A2S8V8C2_9BACI – bp 998 
TAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTAT
AGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGA
GATATACATATGTCTAAGGGGGAAGAGCTGTTCACGGGCGTAGTGCCGATCTTG
GTTGAACTTGATGGTGATGTCAACGGGCACAAATTCAGCGTCAGCGGCGAGGGT
GAGGGCGACGCAACATACGGGAAGTTGACACTGAAGTTTATCTGTACAACTGGG
AAGCTGCCCGTACCCTGGCCCACGTTGGTAACCACCTTCGGGTATGGCGTGCAGT
GTTTTGCGCGTTACCCGGATCATATGAAGCAACACGACTTCTTCAAATCGGCCAT
GCCCGAGGGTTATGTGCAAGAAAGAACGATCTTTTTCAAGGATGACGGTAATTA
TAAGACTCGGGCGGAGGTGAAGTTTGAAGGGGATACCCTTGTAAACCGTATAGA
ACTGAAGGGTATTGACTTTAAAGAGGATGGTAATATATTGGGACACAAGTTAGA
GTACAATTACAACTCACATAATGTTTACATCATGGCCGACAAGCAGAAGAATGG
AATTAAAGTTAATTTTAAGATTCGGCACAACATAGAGGACGGGTCAGTTCAGCTT
GCGGATCATTACCAACAGAACACGCCTATCGGCGATGGCCCTGTCTTGTTGCCGG
ACAACCACTATTTATCCACACAATCTGCTTTGTCCAAGGACCCTAACGAGAAGCG
CGATCATATGGTGTTATTAGAGTTTGTCACCGCCGCAGGGATAACACACGGGAT
GGATGAGCTTTATAAGTAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGAA
GCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCT
CTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTTCG
GGTCATAGCTGTTTCCTG 
 
 
A0A2V2QJP9_9ACTN – 998 bp 
TAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTAT
AGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGA
GATATACATATGAGCAAAGGAGAGGAATTATTTACTGGAGTAGTACCAATCCTT
GTAGAACTGGACGGAGACGTGAACGGCCATAAGTTCTCGGTTTCGGGCGAGGGC
GAGGGTGATGCGACGTATGGAAAACTGACCTTAAAGTTCATTTGCACCACCGGC
AAGTTGCCAGTTCCTTGGCCGACTCTTGTCACAACCCTTACCTATGGAGTACAGT
GCTTTTCTCGGTATCCTGACCATATGAAGCAGCACGACTTCTTCAAGTCTGCTAT
GCCTGAGGGGTACGTTCAAGAGCGGACCATCTTTTTCAAAGATGACGGAAACTA
TAAAACGCGTGCCGAAGTCAAATTTGAGGGTGACACACTGGTAAATAGAATCGA
GCTTAAGGGTATAGATTTCAAGGAGGATGGTAATATCCTGGGTCACAAACTGGA
GTACAACTACAATTCTCACAACGTATATATAATGGCCGATAAACAAAAAAATGG
TATAAAAGTAAACTTCAAGATCCGTCATAATATTGAGGACGGATCGGTCCAGCTT
GCTGATCATTATCAGCAGAACACGCCTATTGGTGATGGGCCCGTTCTTTTACCAG
ACAACCATTACTTGTCTACTCAGTCCGCCCTGAGTAAAGATCCAAATGAAAAGA
GAGACCATATGGTTTTGTTAGAATTTGTTACAGCAGCGGGGATTACCCTTGGAAT
GGACGAATTATACAAGTAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGA
AGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGC
CTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTT
CGGGTCATAGCTGTTTCCTG 
 
 
 
 
127 
A0A2P6SAD1_ROSCH – 1281 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGACCAAAACGACGGCGGCAGCGCAGGCGCTGCCTGGATGTTC
CGACAAGTGTGGCGACCTGACAATCCCGTACCCGTTCGGCATGAATAAGGACTG
CTATTTACGGGAGGAGTTTTTCATAAACTGCTCTAATACAGCCCAGCCACCCACG
GCCTACCTTATGACCTCAAACTTGACTGTCACGAATATAAGCCTTGATGATGGGG
AACTGAGAATACTTAACATGGGAGCCGAGGACTGCTACAACGCCCAGGGTAACG
TGACCTCTAATTTTCCCTACGAGCTGTCCCTTCCGTTACCGTACACCATCTCGTAT
ACTAAAAACAAGTTTTATACGGTGGGTTGCGATTCGCTTTCCATATTCCAGGGAT
TCCGTGGGGAAGACGAGCTTGAAATGGGCTGTATGTCCATGTGTAATCGGCTTG
ACATTGTAGATCAGTACTCCTGTTCGGGAGCAGGCTGTTGTCAAACTAACATACC
TCGCGGCTTGAAAAATGTAACAGTATTACTGGATAGTTTAGATAATCATGCCGGA
ATCTGGGAATTTAACCCCTGCGGTTACGCTTTTATTGCAGAACAAGGGCAGTTTA
ACTTCAGTGCAGCGTCGTTAAAGAAGCAGAACAATTATCAATTACCCTCTGTACT
GAATTGGGCAATCGGCAATGAAACAGATAGCTGCGACGAGGCTCATAAGAAGA
CCAATTTTGCATGTAAGGCTAACTCAATGTGCGTCAACGGTTCGGTAGGATATCT
TTGCCGCTGTTTGCCGGGCTATGAGGGTAATCCGTATCATCCCGACAGATGGTTA
CCGCGTGCAAGCAACTTGTGCCAAAACGGCCAGTGCCTGAACACTTTCCCTCCG
GGGAATTATAGTTGCTCGTGCCATAAAGGGTACAAGAACGATGGTATGAACGAT
AAATCATGCATCGAAGACGACTCCAAGCGCCATAGCAAGATCGTCCTTCTGCTT
ATTGTGTCTCTGGGCATGTATAATTAATAAGTCGACCGGCTGCTAACAAAGCCCG
AAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT
TGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTT
AAACTTCGGGTCATAGCTGTTTCCTG 
 
Chloramphenicol acetyltransferase – 945 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGATGGAAAAAAAAATTACCGGCTATACCACCGTGGATATTAG
CCAGTGGCATCGCAAAGAACATTTTGAAGCGTTTCAGAGCGTGGCGCAGTGCAC
CTATAACCAGACCGTGCAGCTGGATATTACCGCGTTTCTGAAAACCGTGAAAAA
AAACAAACATAAATTTTATCCGGCGTTTATTCATATTCTGGCGCGCCTGATGAAC
GCGCATCCGGAATTTCGCATGGCGATGAAAGATGGCGAACTGGTGATTTGGGAT
AGCGTGCATCCGTGCTATACCGTGTTTCATGAACAGACCGAAACCTTTAGCAGCC
TGTGGAGCGAATATCATGATGATTTTCGCCAGTTTCTGCATATTTATAGCCAGGA
TGTGGCGTGCTATGGCGAAAACCTGGCGTATTTTCCGAAAGGCTTTATTGAAAAC
ATGTTTTTTGTGAGCGCGAACCCGTGGGTGAGCTTTACCAGCTTTGATCTGAACG
TGGCGAACATGGATAACTTTTTTGCGCCGGTGTTTACCATGGGCAAATATTATAC
CCAGGGCGATAAAGTGCTGATGCCGCTGGCGATTCAGGTGCATCATGCGGTGTG
CGATGGCTTTCATGTGGGCCGCATGCTGAACGAACTGCAGCAGTATTGCGATGA
ATGGCAGGGCGGCGCGTAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGA
AGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGC
CTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTT
CGGGTCATAGCTGTTTCCTG 
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PrChi-cat (chitinase) – 1101 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGAAGGTGTTCAGAGAGTATATTGGTGCTTTATATAATGGCGTA
CAATTTACAGACGTACCAATCAACTCCGGTGTGACATTCCATTTTATTCTGGCCTT
TGCTATTGACTATACGAGCGCGGCAGCGGCGACAAACGGAGTCTTCAATATTTA
CTGGCAGAACTCTGTTCTTACACCTGCGGCTGTCCAAGCGATTAAGGCACAGCAC
TCGAATGTCAAGGTGATGGTTTCGTTAGGAGGGGACACCATTAGCGGCTCGCCT
GTCCAATTCACGGCGACAAGTGTCTCATCCTGGGTTGCGAATGCAGTATCATCCC
TGACTTCGTTGATTAATCAGTACCACTTGGACGGCATAGATATTGACTACGAGCA
CTTCGACCAGGTAAGTACATCTACCTTTGTTTCTTGCATTGGGCAGTTAATTACAC
AATTAAAGGCGAACAACGTAATATCGGTTGCGTCGATAGCTCCTTTTGATGGTGT
AGAGTCACAATACACCGCACTTTTTGGTCAATACTCTTCCGTTATCGACTTAGTT
AATTTCCAGTTTTACTCATATGGCGCCGGTACAAGCGCTTCACAGTACGTGTCGC
TGTATAATACTGCCGCGAGTAAATATGGAGGGGGAGCGAAGGTACTGGCAAGTT
TTAGTACGGGTGGAGTCGGACCAGCTCCGTCCACCGTTCTGTCCGCGTGCCAGCA
ACTTAAATCGAGTGGCACCCTTCCAGGAATCTTTATTTTCTCAGCTGATGGGAGC
TACGCGAGTAGCGCGAAGTTTCAGTATGAGCAACAAGCACAGACGTTATTAACC
TCATAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTG
CTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTT
GAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTTCGGGTCATAGCTGTT
TCCTG 
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Subtilisin – 1344 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGGCAGGTAAAAGTAACGGCGAGAAAAAATACATCGTTGGCTT
CAAACAAACGATGTCGACCATGAGCGCAGCGAAAAAGAAAGATGTCATCAGCG
AAAAAGGCGGTAAAGTGCAGAAACAATTCAAATACGTTGACGCGGCCAGTGCCA
CCCTGAATGAAAAAGCAGTGAAAGAACTGAAGAAAGATCCGTCCGTGGCGTACG
TTGAAGAAGACCATGTTGCTCACGCGTATGCCCAGTCCGTTCCGTACGGTGTCTC
ACAAATTAAAGCACCGGCTCTGCATTCGCAGGGCTATACCGGTAGCAACGTTAA
AGTCGCGGTGATTGATAGCGGCATCGACAGTTCCCACCCGGATCTGAAAGTTGC
GGGCGGTGCCAGCATGGTGCCGAGCGAAACCAATCCGTTCCAGGACAACAATAG
CCATGGCACGCATGTGGCGGGTACCGTTGCAGCTCTGAACAATTCTATTGGCGTC
CTGGGTGTGGCACCGTCTGCTAGTCTGTATGCGGTTAAAGTCCTGGGCGCCGATG
GCTCTGGCCAGTACAGTTGGATTATCAACGGTATTGAATGGGCGATCGCCAACA
ATATGGATGTGATCAATATGAGCCTGGGCGGTCCGTCCGGTTCAGCCGCACTGA
AAGCAGCTGTCGACAAAGCAGTTGCTTCCGGTGTGGTTGTTGTGGCCGCAGCCG
GTAACGAAGGCACGTCAGGCTCATCGAGCACCGTGGGTTATCCGGGCAAATACC
CGTCGGTTATTGCGGTCGGTGCCGTGGATTCTAGTAATCAGCGTGCGAGCTTTTC
CTCAGTTGGCCCGGAACTGGACGTTATGGCCCCGGGTGTCTCTATTCAAAGTACG
CTGCCGGGTAACAAATATGGCGCGTACAATGGTACCAGCATGGCATCACCGCAT
GTGGCTGGTGCTGCGGCCCTGATCCTGAGCAAACACCCGAACTGGACGAATACC
CAGGTTCGCTCGAGCCTGGAAAACACCACGACCAAACTGGGCGATTCTTTCTATT
ACGGCAAAGGTCTGATCAATGTTCAGGCAGCTGCGCAATAATAAGTCGACCGGC
TGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATA
ACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAA
GCGAGACTAAGCTTTAAACTTCGGGTCATAGCTGTTTCCTG 
 
 
Anti-GFP – 645 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGCAGGTTCAGCTTGTAGAGAGTGGTGGAGCGTTAGTACAACC
GGGTGGGTCATTGCGGCTGAGTTGCGCGGCATCCGGGTTTCCTGTCAATAGATAC
TCTATGCGTTGGTACCGCCAAGCCCCGGGAAAAGAACGGGAGTGGGTCGCAGGG
ATGAGTAGCGCCGGTGATCGCTCGTCGTATGAGGATTCAGTGAAGGGGCGGTTT
ACGATCTCGCGTGATGATGCTAGAAACACTGTGTATTTACAGATGAACTCTTTAA
AGCCCGAGGACACCGCTGTGTACTACTGCAATGTAAATGTAGGTTTCGAGTACTG
GGGGCAAGGGACACAGGTAACGGTCTCGACTTCACATCACCACCATCATCACTA
ATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCC
ACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGG
GGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTTCGGGTCATAGCTGTTTCCT
G 
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BP100 – 321 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGAAGAAACTTTTTAAAAAAATTTTGAAATATTTGTAATAAGTC
GACCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTG
AGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTT
GCTGAAAGCGAGACTAAGCTTTAAACTTCGGGTCATAGCTGTTTCCTG 
 
 
CA(1-7)M(2-9) – 333 bp 
GTAAAACGACGGCCAGTAGCGCTATTAAAGCTTCGAAATTAATACGACTCACTA
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGG
AGATATACATATGAAGTGGAAATTATTTAAGAAGATTGGAGCTGTATTAAAAGT
CTTATAATAAGTCGACCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCT
GCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTC
TTGAGGGGTTTTTTGCTGAAAGCGAGACTAAGCTTTAAACTTCGGGTCATAGCTG
TTTCCTG 
 
 
sfGFP Expression on a Molar Basis 
The following figures are used to compare the efficacy of the various genetic 
templates used in these experiments on a mass basis and molar basis. The templates explored 
were: plasmid pJL1-sfGFP (gift from Jewett lab), linear expression template, circular 
expression template, and rolling circle amplified template. 
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Figure S4.1 - Kinetic plot of sfGFP expression templates on a molar basis. All genetic 
templates had a final concentration of 0.0061 pmoles/µL (0.0061 µM). 
 
 
Figure S4.2 - Kinetic plot of sfGFP expression templates on a mass basis. All genetic 
templates had a final concentration of 10 ng/µL. 
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GFP Variants and Homology 
This section contains plots of GFP variants and figures that were obtained using Expasy’s 
sequence alignment SIM tool 
 
 
Figure S4.3 - Kinetic plot 4 previously uncharacterized GFP variants obtained from Uniprot. 
The emission/excitation for this plot was 400/509 nm with a bandpass window of ±20. 
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Figure S4.4 – Kinetic plot of a putative GFP obtained from the Uniprot database. The 
emission/excitation window for this plot was 485/528 nm. The Expasy SIM sequence 
alignment tool was unable to find an overall degree of homology. 
 
Figure S4.5 – Kinetic plot of a putative GFP obtained from the Uniprot database. The 
emission/excitation window for this data was 385/460 nm. The Expasy SIM sequence 
alignment tool was unable to find an overall degree of homology. 
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Figure S4.6 – Sequence alignment of the first (A0A125NTU3_HYPSL) GFP variant as 
compared to native GFP. 
 
 
 
Figure S4.7 – Sequence alignment of the second (K0NYR4_9CAUD) GFP variant as 
compared to native GFP. 
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Figure S4.8 – Sequence alignment of the third (A0A2S8V8C2_9BACI) GFP variant as 
compared to native GFP. 
 
 
 
 
 
 
Figure S4.9 – Sequence alignment of the fourth (A0A2V2QJP9_9ACTN) GFP variant as 
compared to native GFP. 
 
Figures Used in Cost Calculations 
The following figures represent data used to render a cost analysis between an in-
house cytomim system and the Promega Premix Plus that comes with an S30 High Yield 
commercial kit.  All cost calculations are shown in an attached Excel worksheet. 
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Figure S4.10 – Kinetic plot of sfGFP using the supplements made in our lab. The results 
from this figure were used for the cost analysis. The final concentration of protein was found 
to be 109.19 µg/mL using our fluorescent calibration below. 
 
 
Figure S4.11 – Kinetic plot of sfGFP pJL-1 plasmid vs RCA on our template using the 
components of the Promega S30 High Yield kit. The results from this figure were used for 
the Promega kit cost analysis. The concentration of protein was 40.52 µg/mL. 
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Figure S4.12 – Kinetic plot of sfGFP pJL-1 plasmid vs RCA performed on pJL-1 plasmid vs 
RCA performed on our minimal template. This was done with the Promega extract but using 
an in-house NMP-based PANOx-SP supplement mixture [1]. This was not used in cost 
calculations since it was not wholly Promega. 
 
 
Figure S4.12 – Calibration curve determined empirically by our group to determine the 
concentration of sfGFP with the equation y = 0.0048x – 6.1036 where x is the fluorescence 
and y is the concentration of sfGFP in µg/mL. The R-squared value for the linear regression 
is 0.993. 
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Figure S4.13 – Pie charts breaking down percentages of the total cost of expression of 1 mg 
of sfGFP using minimal RCA templates. All values were adjusted based on estimates for 
how many reactions it would take to produce 1 mg of sfGFP using reagents manufactured in-
house versus those from a Promega T7 S30 High Yield kit. There is no extract cost for the 
Promega chart since the cost of the entire kit is built into the supplement cost. 
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CHAPTER 5.    CONCLUSIONS AND FUTURE WORK 
In conclusion, our lab has shown that CFPS is an excellent tool for rapid protein 
screening. Through a wise selection of an energy system and supplement optimization, a cell-
free expression system can be tailored to the needs of the individual. We have detailed an 
efficient way to make highly active cell extract by using a designed experiment to maximize 
expression. This scalable method simplifies the workflow for a graduate student and opens 
more time for other lab duties. We have also developed a novel method of DNA 
amplification that could pave the way for new protein engineering experiments. 
5.1 Fusion Proteins for Therapeutics 
One possible direction for our system is prototyping new fusion proteins for 
therapeutic use. Fusion proteins have been expressed using CFPS in the past and have been 
found to reduce proteolytic degradation of antimicrobial peptides [1]. Elastin-like peptides 
(ELPs) are a very interesting fusion candidate since they have been shown to aid in drug 
delivery to articular joints. The drug of interest was not cleared from the joint as quickly 
when it was attacked to a thermally responsive ELP [2]. ELPs have also been used to purify 
proteins expressed in vivo since they can be tuned for solubility at different temperatures [3]. 
These ELPs may be able to serve a dual purpose of offering simplified purification while 
improving the therapeutic effect of proteins [4]. 
5.2 Prototyping Nanobodies 
A very interesting class of compounds with interesting applications is that of 
nanobodies. Nanobodies are single domain antibodies, also referred to as VHHs, isolated 
from camelids. Nanobodies are typically have a molecular weight around 15 kDa while a 
human IgG is much larger at 150 kDa [5]. Nanobodies offer superb thermal stability and 
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have already been incorporated into caffeine sensors [5,6]. They are capable of penetrating 
cells in order to reach their specific antigen [7] and have even been engineered to cross the 
blood-brain barrier as a fusion protein [8]. In fact, the company Ablynx is currently 
conducting clinical trials on an anti-IL-6R nanobody for treating rheumatoid arthritis. The 
name of this nanobody is ALX-0061, or Vobarilizumab [9]. Nanobodies are also being 
developed to target tumor cells [10]. The CFPS methods outlined in this thesis could be used 
to rapidly screen the most effective nanobodies for a desired application. An anti-GFP 
nanobody as already been expressed using CFPS by the Collins group [11] and in an earlier 
chapter of this thesis. It would be possible to pick an antigen of interest and use site-directed 
mutagenesis to produce a DNA library of possible candidates. High throughput screening 
could then be implemented using CFPS. For example, a single 96-well plate can support 96 
different CFPS reactions, each containing a different DNA variant. Depending on the energy 
system chosen, these variants could be ready for screening in a matter of hours. It would even 
be possible to use ribosome display since it is an in vitro method of screening [12,13]. 
Development of a microfluidic method to analyze the binding of nanobody candidates could 
improve workflow by reducing the screening time and reducing the amount of raw materials 
(extract, supplements, DNA) needed through the use of microreactors [14]. Successful 
candidates could then be expressed as fusions with ELPs to simply purification and used for 
in vivo studies. CFPS for nanobody engineering can be taken a step further by introducing 
non-natural amino acids. This isn’t possible when expression proteins in vivo but the 
incorporation of non-natural amino acids in vitro has been around for some time. This would 
allow for interesting click chemistry to be performed where a drug payload could be attached 
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to the most successful nanobody candidate [5,15]. There are many more possible applications 
for engineered nanobodies [5,16,17] that can be explored with our CFPS system. 
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